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ABSTRACT
Glutathione (GSH) plays an essential role in the intracellular antioxidant defense
against the oxidant radicals, especially the -OH radical. To understand the early and
progressive cellular changes in Alzheimer's disease (AD) development, we investigated
reduced glutathione/oxidized glutathione (GSH/GSSG) status in a double mutated AD
transgenic mouse model (B6.Cg-Tg), which carries Swedish amyloid precursor protein
mutation (APPswe) and exon 9 deletion of the PSEN1 gene. Likewise, S-glutathionylation
(Pr-SSG) is a specific post-translational modification (PTM) of cysteine residues by the
addition of glutathione. S-glutathiony 1ated proteins induced by oxidative stress play an
essential role in understanding the pathogenesis of the aging and age related disorder. In
addition, 8-Hydroxy-2'-deoxyguanosine (8-OHdG) is one of the major forms of DNA
oxidative damage, and is commonly analyzed as an excellent marker of DNA lesions.
The purpose of this research was to develop a sensitive method to accurately and rapidly
quantify the 8-OHdG by using capillary electrophoresis with laser-induced fluorescence
detection (CE-LIF). The method involved the use of specific antibody to detect DNA
lesions (8-OHdG) and consecutive fluorescence labeling.
Here, we quantified and compared both GSH/GSSG and mixed-disulfide (PrSSG) levels in blood samples and three anatomic positions in the brain (cerebrum,
cerebellum, and hippocampus) at 3 age stages (1-, 5-, and 11-month-old) of AD
transgenic (Tg)/wild type (WT) mice. The study was designed to characterize and
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provide insight into the glutathione redox state of both brain tissues and blood samples at
different disease stages of this Tg model. The GSH/GSSG ratio in AD-Tg brain tissue
started at a higher value at 1-month, fell at the transitional period at 5-month, right before
the onset of amyloid plaque, followed by an increase in GSSG and an associated decrease
of GSH/GSSG at 11-month. Besides, the high basal levels of Pr-SSG in hippocampus
suggest a potential for increased oxidative damage under oxidized conditions and
increased GSSG in this vulnerable region.
Moreover, we developed an approach to aid in the early diagnosis of AD by using
principal component analysis (PCA) based spectral analysis of oxidized protein
electrophoretic profiling. We found that the combination of capillary electrophoresis and
PCA analysis of S-glutathionylation distribution characterization can be used in the
sample classification and molecular weight (Mw) prediction. PCA can project the Sglutathionyl electrophorectic data into one of six different groups of mice brain and blood
samples based on disease progressions and genotype differences. The prediction of the
main protein Mw regions that are most susceptible to S-glutathionylation damages in
mice brains and blood samples are located at 8.4-20.3 kDa and 13.2-37.2 kDa.
Furthermore, the urine sample with 8-OHdG fluorescently labeled along with
other constituents was resolved by the capillary electrophoretic system and the lesion of
interest was detected using a fluorescence detector. The low detection limit of 9.0 amol
proves the method sensitive enough for the detection and quantification of 8-OHdG in
untreated urine samples. The relative standard deviation (RSD) was found to be 11.32%
for migration time, and 5.52% for the peak area.
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CHAPTER 1

INTRODUCTION

1.1

Alzheimer's Disease

In 2011, there were 5.1 million cases of Alzheimer's disease (AD) in the U.S.,
while the number of individuals affected by AD is expected to increase over double with
the expanded aging population by 2050 [1]. The prevalence of AD patients will reach up
to 106.8 million people worldwide by 2050. In other words, 1 in 85 persons has the risk
of getting AD in 38 years [2], It was also estimated that the primary family members and
other relatives had put in 17 billion hours of unpaid care that was commensurate with
more than $202 billion in 2010 [1]. Many studies suggest that unpaid caregivers often
suffer from depression and stress that can directly result in low life qualities and high
financial challenges. According to the report from the Center of Disease Control (CDC),
the medical and nursing care bills might cost $1 trillion annually by 2050 [3]. Moreover,
the National Institutes of Health (NIH) will soon add an additional $50 million along with
the $450 million/year funding in dementia or AD research this year. "The science of
Alzheimer's disease has reached a very interesting juncture. We would love to be able to
come up with a way of bringing forward an even larger amount of support," NIH director
Dr. Francis Collins said in Feb. 8th, 2012.

1

2

AD often has a long stage of neuropathological changes and cognitive decline
starting at a molecular level, possibly decades earlier than when the decline is detected by
neuropsychological testing [4, 5]. Oxidative stress induced by reactive oxygen species
(ROS) and a disturbance of glutathione homeostasis in the brain has been implicated as a
contributing factor to Alzheimer's disease [6].

1.2

Glutathione Redox Cycle

The homeostasis of the brain redox status is mainly controlled by glutathione
(GSH) that functions in radical scavenging and protecting cells from oxidative stress [7,
8]. GSH is the most abundant non-protein thiol [9] and is the first line of defense against
superoxide anions and OH radicals produced in mammalian cells [10, 11]. Free (non
protein bound) glutathione exists primarily in its reduced form (GSH), which can be
oxidized to glutathione disulfide (GSSG) during oxidative stress [12]. GSH is regenerated
from GSSG in the glutathione redox cycle catalyzed by GSSG reductase (GR) at the
expense of reduced nicotinamide adenine dinucleotide phosphate (NADPH). GSSG,
when elevated, can promote protein-protein or protein-lipid cross-linkage [13]; the
generation of protein mixed-disulfides (Pr-SSG) involves thiol/disulfide exchange
between GSSG and Cys residues on proteins [14]. Thus, enhanced levels of GSSG may
increase formation of Pr-SSG [15] shown in Figure 1.

3

NADP+

SOD
H202*— 0;

GSH
jER

GP

J

NADPHiI^^gssg^VH 2 O

r
Pr-SH — P r - S S G

Figure 1: Glutathione Redox Cycle. Oxidative stress, which is a disturbance of
glutathione homeostasis, induced by Reactive Oxygen Species (ROS). Superoxide
dismutase and Glutathione (GSH) are considered as the first line of defense against
superoxide anions and OH radicals produced in mammalian cells. Glutathione presents
primarily in its reduced form (GSH), which can be converted to the oxidized form
(GSSG) under glutathione peroxide (GPx). GSSG is then recycled to GSH by glutathione
reductase (GR) in the presence of reduced nicotinamide adenine dinucleotide phosphate
(NADPH).

1.3

Oxidized Protein

GSH exists in both free and protein-bound (S-glutathionylated) forms. The free
form of glutathione exists primarily in its reduced form (GSH), which can be converted
to the oxidized glutathione disulfide (GSSG) during oxidative stress. The Sglutathionylation of protein (Pr-SSG), representing an important post-translational
modification (PTM), plays an essential role in studying the etiology of the aging disorder,
such as Alzheimer's disease (AD). The pathway to generate Pr-SSG involves
thiol/disulfide exchange between GSSG and thiol residues at Cys residues on proteins
[14]. GSSG, when elevated, can promote this thiol/disulfide exchange and cause a greater
expression of Pr-SSG [15]. Currently, the S-glutathionylation is investigated to elucidate
pathological changes in AD, because some proteins are sensitive to cysteine oxidation
initiated by increased oxidative stress in an AD brain [16, 17]. Using a redox proteomic
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approach, several proteins have been identified as specific targets of S-glutathionylation
in AD [16, 17]. For instance, Glyceraldehyde 3 phosphate dehydrogenase (GAPDH), a
well-known enzyme in intermediary metabolism, plays a crucial role in AD [17]. These
oxidatively modified proteins in the AD brain demonstrate impaired protein function,
which result in altered cell function, apoptosis and the development of amyloid plaques
[16, 17]. Also, studies show that S-glutathionylation has potential to serve for redox
regulation mechanism [18], Several methods have been developed so far to quantify the
free (non-protein bound) glutathione. To study GSH, proteins existing as the most
abundant component in biological samples are removed by either acidification or
ultrafiltration

to

eliminate

interference

[19,

20].

Additionally,

prior

to

the

chromatographic or electrophoretic analysis of GSH, determination of total GSH requires
the reduction of all disulfide, which can be achieved enzymatically by glutathione
reductase (GR) [21] or chemically with various reducing compounds such as
Dithiothreitol (DTT) [22,23],

1.4

DNA Lesion

Both nuclear and mitochondrial DNA from various tissues and white blood cells
are subjected to oxidative damage [24]. They interact with reactive oxygen species (ROS)
including superoxide anion radical (C>2~), hydrogen peroxide (H202), hydroxyl radicals
(•OH), and further produce more than 20 oxidized DNA adducts. Among them, one of the
major types of DNA damage is 8-hydroxy-2'-deoxyguanosine (8-OHdG) shown in
Figure 2 and is considered as the most commonly used biomarker for evaluation of
cellular oxidative stress. The role of 8-OHdG is implicated in aging and the development
of neurodegenerative disease such as Alzheimer's disease (AD). It has been a well-

5

studied biomarker of oxidative stress, since it can cause mutations through CG to AT
trans versions [25]. Because guanine has the lowest oxidation potential when compared
with the other DNA bases, it is easy to oxidize and further forms the most abundant and
important marker of oxidative damage stress. The mechanism of formation involves
attack on the C8 of guanine by the hydroxyl radical followed by the formation of guanine
C8-OH adduct radical that may undergo two separate pathways: (1) FapyGua formation
or (2) subsequent oxidation and formation of 8-oxoguanine [26].

/NH

NH-\

N

HO—/

Oxidative Stress
OH

Deoxyguanosine

V_

H2N ^^A oh)

HO

'

OH

8-OHdG

Figure 2: Formation of 8-hydroxy-2'-deoxyguanosine (8-OHdG) by oxidative stress.

Oxidative DNA damage accumulates in the brain. Oxidative damage is a
contributing factor for development of Alzheimer's disease and is a major component of
aging. Age-dependent increases of 8-OHdG were found in various tissues, such as the
human pituitary gland [27], the liver and kidney of rats [28, 29], the human cerebral
cortex and the cerebellum brain [30]. Because high oxygen is consumed by the brain, AD
brains are most likely susceptible to oxidative damage. The evidence indicates that
oxidative DNA damage is the feature of AD in the brain and ventricular CSF [31, 32].
The gas chromatography/mass spectrometry (GC/MS) study of temporal and parietal
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lobes of the brains of AD patients revealed statistically significant increases of 8-OHdG
in the AD patients when compared to the control subjects [32]. Studies have reported that
the levels of 8-OHdG were increased in the mitochondrial DNA of patients with late AD
when compared to nuclear DNA [32-34]. 8-OHdG levels were characterized as elevated
in mitochondrial DNA in the cerebral cortex of AD patients compared with controls [35].
Another study detected higher levels of 8-OHdG in the nuclear DNA of lymphocytes in
patient that have AD disease [36]. A recent study by Lovell's group found the significant
increase in 8-OHdG in multiple brain regions, including frontal, temporal and parietal
lobes in mild cognitive impairment (MCI) subjects [32], These findings suggest oxidative
DNA damage occurs at the earliest detectable phase of AD, and it may serve as a
prescreening tool for AD and play a critical role in AD pathogenesis.
Oxidative DNA damage is also found in the urine. After 8-OH-dGTP is formed in
the nucleotide pool, the pyrophosphate can be removed by the enzyme MTH1 to yield
80H-dGMP. Afterwards, it is digested by 5'(3')-nucleotidase to produce 8-OHdG.
Without further metabolism, 8-OHdG is excreted in urine [37, 38]. Because the amount
of 8-OHdG excreted in the urine corresponds to the average rate of oxidative damage in
the whole body, it can be potentially used as a medical test of early screening for
different diseases. Measurement of excreted repair products in urine indicates the average
rate of the damage in the total body, while the abundance of oxidized bases in nuclear or
mitochondrial DNA represents the concentration in the specific local tissues/cells.
Compared to DNA samples, urine is a better matrix for analyzing 8-OHdG, since DNA
isolation and digestion techniques usually are the source of artificial formation of 8OHdG [39]. Also, because 8-OHdG is excreted in the urine, it can be used as a non-
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invasive assay for determining the levels of in vivo oxidative lesions in the early
development various diseases, such as cancer, diabetes, atherosclerosis and neurological
disorders [40]. Here, we focus on the development of a sensitive assay to monitor 8OHdG in AD urine sample. This method has a great potential to serve as a platform to
evaluate the effect of AD therapy. Overall, my research has been focused on three
projects, which are (1) the study of glutathione redox status, (2) the prediction of Sglutahtionylated protein profile, and (3) the detection of damaged DNA.

CHAPTER 2

METHODS

2.1
2.1.1

General Methods

Transgenic Mice and Genotyping
AD-Tg mice [B6.Cg-Tg (APPswe, PSENldE9) 85Dbo/J, stock no. 005864, Bar

Harbor, ME] were purchased from Jackson Laboratory. Real time polymerase chain
reaction (qPCR) and melting curve analysis (HRM) were used for genotyping of the ADTg mice. The primer sets for the APP transgenic gene are (forward 5'-GAC TGA CCA
CTC GAC CAG GTT CTG-3% reverse 5'-CTT GTA AGT TGG ATT CTC ATA TCC
G-3') [41]. Primer sets for the PS1 mutant gene are (forward 5'-AAT AGA GAA CGG
CAG GAG CA-3', reverse 5'-GCC ATG AGG GCA CTA ATC AT-3') as shown in
Table 1. DNA was extracted by immersing a mouse tail snip in 25 mM NaOH/O.2 mM
EDTA at 98° C for 1 hour. The extracted DNA samples were mixed with 40 mM TrisHC1 (pH 5.5) and centrifuged at 4,000 rpm for 3 min. The sequence of APP gene was
amplified by quantitative PCR and then analyzed by melting curve analysis using a LC
32 Scanner (Idaho Technology, Utah). The melting temperature of the App gene is 86.0 ±
0.6° C.
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Table 1: The sequence of oligomers.

Oligos
APP forward
APP reverse

2.1.2

Sequence
5'-GAC TGA CCA CTC GAC CAG GTT CTG-3'
5'-CTT GTA AGT TGG ATT CTC ATA TCC G-3'

Use
PCR
PCR

Cell Culture
The human colon epithelial cell line HT-29 was used as a proof of principle in

this method and was grown in McCoy's medium supplemented with 10% fetal bovine
serum, penicillin (100 units/ml), streptomycin (100 units/ml), and incubated in 5% CC^at
37° C [42]. For the menadione (MQ)-mediated oxidative stress treatment, cells were
treated with 200 |iM MQ for 30 min in serum-free DMEM (Dulbecco's Modified Eagle's
medium) [43]. After gentle rinsing, scraping cells into cold phosphate-buffered saline
(PBS) with a scraper and then centrifugation (radius of rotor = 10 cm) at 112xg, cell
pellets were harvested and immediately frozen in liquid nitrogen. For cell lysis, cells
were sonicated in 250 //L IX PBS with 2% SDS for 20 min at 4° C [44]. The same
procedures were applied to untreated HT-29 cells.
2.1.3

Sample Preparation
In this initial study, whole blood samples and brain tissue were isolated from one

pair of 5-month AD-Tg/wild type (WT) mice. The mice were anesthetized using sodium
pentobarbital (60 mg/kg) through an intraperitoneal injection and perfused transcardially
with ice-cold saline. The brains were rapidly removed and dissected on ice to harvest
three brain regions including the cerebrum, the cerebellum and the hippocampus. The
sample was rinsed with ice cold PBS and stored in -80° C for further study. After
homogenization of the brain tissues, proteins from each preparation was precipitated in
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5% trichloroacetic acid (TCA) at 4° C for 15 min, and centrifuged at 10,000xg for 5 min.
The protein pellets were kept and then dissolved in PBS solution with 5% SDS at pH 8
[45, 46]. All procedures for the handling of mice were approved by the Institutional
Animal Care and Use Committee at Louisiana Tech University.
2.1.4

Protein Concentration Measurement
The BCA assay kit was used to measure the protein concentration according to

the manufacturer's protocol. The absorbance of the protein samples at 562 nm was
determined by a NanoDrop 2000/2000c Spectrophotometer.
2.1.5

Data Analysis
Igor Pro software (Wavemetrics, Lake Oswego, OR) was utilized to analyze data

and electrophorograms, including migration time and peak area for each individual
sample. To generate a calibration curve of S-glutathionyls, in vitro S-glutathionylated
bovine serum albumin (BSA-SSG) was used for plotting S-glutathionyls amounts with
respect to fluorescence peak area. Therefore, amounts of Pr-SSG from HT-29 cells and
brain tissue and whole blood of AD-Tg/W mice were calculated based on this curve.
Statistical analysis between groups was done by one-way ANOVA. A value of P < 0.05
was accepted as significant. All values are expressed as mean ± SEM; n=5 for each
group.

2.2
2.2.1

High Performance Liquid Chromatography

Measurement of GSH and GSSG
The levels of GSH and GSSG in brain homogenates and blood samples of AD-

Tg/WT mice at 3 stages were measured using HPLC [43] after TCA precipitation. Acidsoluble GSH and GSSG were derivatized as follows. GSH was first reacted with 80 mM
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iodoacetic acid (IAA), a thiol alkylating agent to form the S-carboxymethyl derivatives of
free thiols [47]. Then 6% l-fluoro-2, 4-dinitrobenzene (FDNB) was added to react with
free amine groups to form 2, 4-dinitrophenyl derivatives [48]. The chromatograph of
GSH and GSSG derivatives was performed on a 250 mm x 4.6 mm Alltech Lichrosorb
NH2 10-|j.m column using a Shimadu HPLC system. GSH and GSSG contents were
expressed as nanomole per milligram protein, which allowed the calculation of the
glutathione redox ratio (GSH/GSSG).
2.2.2

Pr-SSG Determination
Pr-SSG was determined using a modified Ellman's assay. After TCA

precipitation and centrifugation at 10,000xg for 5 min, the protein pellets were obtained
and then dissolved in IX PBS solution with 5% SDS at pH 8 [45], After the protein
pellets completely dissolved, the samples were split into two sets. Set I was pretreated
with 40 jal immobilized TCEP gel to reduce all disulfides in Pr-SSG to protein thiols (PrSH) at 37° C for 30 min with occasional shaking. Set I (containing reduced Pr-SH and
native Pr-SH) and Set II (containing only native Pr-SH) were incubated at room
temperature for 15 min with 70 j_il phosphate buffer (1.5 mM KH2PO4, 6.36 mM
K2HPO4, 1.57 mM EDTA) containing 3.95 mM DTNB. Total Pr-SH (Set I) and native

Pr-SH (Set II) were determined spectro-photometrically at 412 nm [49]. The
concentration of disulfides in Pr-SSG (nmol disulfides/mg of protein) was expressed as
half of the thiols determined from the difference between Set II and Set I [50]. The
quantity of mixed-disulfide is overestimated because other cysteine modifications such as
S-nitrosylation and S-sulfenation also occur and are reduced by TCEP in sample
preparation from Set I group. However, this overestimation is minimal and negligible
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since mixed-disulfide (Pr-SSG) is much more predominant with nearly 1000 fold higher
expression than endogenously low abundant nitrosylated proteins (1-200 picomole/mg
protein) [51-53].
2.2.3

Determination of Enzymatic Activity
Glutathione reductase (GR) and glutathione peroxidase (GPx) activities

(nmol/min/ml) were determined using commercial GR and GPx assay kits from Cayman
Chemical Company. In total, the brain tissues from three pairs of mice at each three
stages (1-, 5- and 24-month old) were analyzed and the sample preparations were
followed according to the manufacture protocol.

2.3
2.3.1

Capillary Electrophoresis

In Vitro S-glutathionylation of BSA
Five mg/ml BSA solution was obtained by dissolving BSA in 50 mM Tris/1 mM

EDTA with 0.1% SDS at pH 7.5, and mixed with 5 mM DTT at 37° C for 1 hour [54].
Because native BSA has few free thiol groups, DTT was used to reduce exposed
disulfides from denatured BSA after treating with 0.1% SDS [55]. DTT was then
removed by using spin columns before subjecting BSA to 2.5 mM diamide at 37° C for
30 min to generate S-glutathionylation in vitro [54, 55]. After desalting using spin
columns to remove diamide, final concentration of in vitro S-glutathionylated BSA was 5
mg/ml.
2.3.2

S-glutathionyl Level Determination
The S-glutathionyl level in BSA-SSG was determined using modified Ellman's

assay [46, 56]. After neutralizing the BSA-SSG to pH 8, the samples were split into two
sets (40 fil of 5 mg/ml S-glutathionylated BSA each). Set I was pretreated with 40 p.1
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immobilized TCEP gel to reduce all disulfides into thiols at 37° C for 30 min with
occasional shaking. Hence, Set I contains total thiols of Pr-SH (reduced Pr-SH and native
Pr-SH), whereas Set II contains only native Pr-SH. Both sets were incubated with 70 |al
phosphate buffer (1.5 mM KH2P04, 6.36 mM K2HP04,1.57 mM EDTA) that contains
3.95 mM DTNB at room temperature for 15 min. Total Pr-SH and native Pr-SH were
subsequently determined spectrometrically at 412 nm from Sets I and II, respectively
[49]. Hence, the concentration of S-glutathionyls in BSA-SSG (nmol glutathiols/mg of
BSA) was quantified and determined as half of the thiols difference between Set II and
Set I.
2.3.3

Pr-SSG Derivatization and Detection
This procedure comprises of blocking the native thiols using N-ethylmaleimide

(NEM), the deglutathionylation of SSG into free sulfhydryl (-SH) group followed with
fluorescence labeling of the newly formed SH group by Dylight 488 maleimide (as
shown in Figure 3a). The derivatized samples were then separated using size-based
capillary gel electrophoresis with laser induced fluorescence (CE-LIF) detector. The
deglutathionylation assay (depicted in Figure 3b) is based on the precise enzymatic
recycling reaction using Grx-3, and includes the following three steps [57, 58]: (1)
Specific reduction of Pr-SSG by Grx-3 to generate newly formed Pr-SH, (2) The
tripeptide, GSH from Grx-SSG intermediate is transferred to GSH to generate GSSG, and
(3) Glutathione reductase (GR) reduces GSSG with the presence of NADPH.
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Figure 3: Mechanism of deglutathionylation and detection of S-glutathionylated proteins
(Pr-SSG). (a) Schematic representation of the method to detect Pr-SSG by labeling with
Dylight 488 maleimide. (b) Deglutathionylation assay is divided by 3 steps. (1) The PrSSG is reduced by glutaredoxin (Grx). (2) The oxidized Grx (Grx-SSG) intermediate is
transferred to glutathione (GSH). (3) Glutathione reductase (GR) reduces oxidized
glutathione (GSSG) with presence of nicotinamide adenine dinucleotide phosphate
(NADPH).

Briefly, for alkylation of free thiol groups, a 20 jj.1 protein sample of each
preparation (in vitro BSA-SSG, MQ induced HT-29 cells, brain tissues and whole blood
from AD mouse model) was incubated in 40 mM NEM and 25 mM HEPES, 0.2 mM
EDTA, 0.01 mM neocuproine and 2.5% SDS at pH 7.7 for 30 min at 4° C [44, 54]. The
excess NEM was removed by extensive wash (6 washes) with spin columns (molecular
weight cut-off 3 kDa). The washing solvent was PBS at pH 7.4 and each wash involved
centrifugation at 4000xg for 20 min. For deglutathionylation, the blocked Pr-SSG sample
was subsequently incubated with 2.5 ng/ml Grx-3, 4 U/ml GSSG reductase, 1 mM GSH,
1 mM NADPH for 50 min at 37° C [58]. The excess GSH and NADPH were removed by
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using spin columns again. Last, for the labeling of newly generated free thiols, 2 |_il of
12.5 mM Dylight 488 maleimide was used and vortex mixed overnight. The excess dye
was later removed by spin columns with obtaining a final volume of the protein sample
of 100 \xl
2.3.4

Validation of the Developed Method
Various controls were performed to validate the selectivity of S-glutathionyl

labeling of the method. These controls included: (a) 1.25 (iM Dylight 488 maleimide dye
alone; (b) BSA-SSG without Grx-3 catalyzed deglutathionylation step; (c) BSA-SSG
pretreated with 5 mM DTT to reduce the protein bound disulfides; (d) native BSA
without S-glutathionylation; and (e) MQ treated HT-29 cells without Grx-3 reduction.
Additionally, we investigated (i) desalting efficiency of NEM and (ii) NEM
alkylating efficiency.

Excess

blocking

reagent

needs

to

be

removed

before

deglutathionylation to avoid alkylation of freshly reduced disulfides, which could cause
underestimation of Pr-SSG. On the other hand, incomplete NEM blocking of free thiols
will result in false artifacts of Pr-SSG signals.
2.3.5

CE Instrument
CE with LIF has been considered as a highly efficient, sensitive and fast

analytical separation technique for the analysis of low abundance of proteins. A
commercial capillary electrophoresis instrument, Beckman Coulter P/ACE MDQ system
(Fullerton, CA) was used for the analysis of modified protein or damaged DNA. For
excitation, the LIF detector used an argon-ion laser (488 nm line, 3 MW) that was
directed to a detector window in the capillary using a fiber optic [59]. A 520DF20
bandpass filter (~510-530 nm) was used to select the Dylight 488 fluorescence emission
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before the photo-multiplier tube (PMT). The PMT output signals were sampled at 4 Hz.
Separation was carried out using a 30.8-cm-long, 50-//m-i.d., 361-^m-o.d. fused-silica
capillary. UltraTrol LN, a class of linear polyacrylamide made of yV-substituted
acrylamide copolymers, was used for pre-coating the capillary walls to decrease the
electroosmotic flow (EOF) and inhibit protein binding to the capillary wall [60]. The
sample was injected hydrodynamically at 11 kPa for 4 seconds into the capillary
containing the sieving matrix buffer, which consisted of 15% dextran (64-76 kDa), 0.5%
SDS, 20 mM Tris and 20 mM Tricine. Separation was performed at -570 V/cm. The
capillary was reconditioned between consecutive runs with sequential pressure-driven
flushes (20 psi) of 0.5 M sodium hydroxide for 5 min, H2O for 3 min, the dynamic
coating reagent UltraTrol LN for 2 min, the separation buffer for 2 min, and the sieving
matrix buffer for 4 min. The separation buffer consisted of 20 mM Tris, 20 mM Tricine
and 0.5% SDS at pH 8.
2.3.6

Mw Determination
Five protein standards, including trypsin inhibitor, GAPDH, albumin from

chicken egg white, BSA, BGG with different molecular mass ranging from 20 to 140
kDa, were measured using CGE-LIF. To transform the migration time into protein
molecular weight (Mw), the standard curve between the logarithm of the protein's size
and electrophoretic mobility was calculated. The relationship is shown in Figure 4.
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Figure 4: Transformation of migration time (a) to molecular weight (Mw) value, (b) Log
of molecular mass of standard proteins as a function of their electrophoretic mobility.

2.3.7

Urine Collection and Labeling
Urine samples were collected from male, 11-month-old, AD transgenic mice.

After collection, the samples were centrifuged for 10 min at 4000 rpm and the
supernatants were collected and stored at -20° C for further analysis. In order to detect 8OHdG in the AD mice urine samples, a 20 |iL urine sample was incubated with 20 |iL
mix of the primary (40 ng-^L'1) and 10 |iL secondary antibody (40 ng-|iL"') for lh on
orbital shaker, 500 rpm, at room temperature.
2.3.8

Labeling of Test Model
A DNA oxidative stress model, 8-OHdG was used to test the labeling scheme and

validate the LIF detector response. 8-OHdG (1 mg) was suspended in 50 |iL DMSO and
9950 fiL of water to reach a final concentration of 100 ng-fiL"1 (or 353 |^M). Anti-8OHdG and the secondary Alexa 488 antibody were diluted in water. To generate the
calibration curve, five 8-OHdG standards with final concentrations of 10, 8, 6, 4, and 2
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ng-(jL"' were prepared. Twenty jiL of 8-OHdG standard, 20 |iL of primary antibody (40
ng-fjL"1), and 10 (iL of secondary antibody (40 ng-jiL"1) complex were mixed. 8-OHdG
was incubated on the orbital shaker with anti-8-OHdG antibody at room temperature at
500 rpm for lh. The secondary antibody was added to the mix and the sample was
incubated for another hour on an orbital shaker at 500 rpm. Five 8-OHdG standard
complexes were injected in the CE-LIF instrument to generate the standard curve and
further estimate the limit of detection.
2.3.9

Separation Condition
Sodium Tetraborate buffer (pH 9.5) was used as the carrier electrolyte for all

determinations. Samples were injected into the capillary containing the separation buffer
using hydrodynamic injection mode at a pressure of 0.5 psi with 5 sec injection time.
The separations were performed at 400 V/cm. Measurements were carried out at constant
temperature, 25° C. The capillaries were preconditioned using methanol for 5 min,
followed by 1M NaOH for 10 min, 1M HC1 for 10 min, water for 10 min, and sodium
tetraborate buffer for 10 min. After each run the capillaries were washed with 1M NaOH
for 5 min, followed by water for 2 min and sodium tetraborate buffer for 3 min.

2.4
2.4.1

Principle Component Analysis

Principle Component Analysis
PCA was then applied to the Pr-SSG profiling spectrum data to extract the

reduced feature set. The molecular weights of the Pr-SSG were predicted after PCA.
Based on the distribution of the electropherographical data projected onto the PCs, Kmeans clustering technique [61] and probability for Gaussian distribution [62, 63] were
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applied to classify the age and genotype of the samples from the complex S-glutathionyl
profiles. A block diagram summary of the overall procedure is illustrated in Figure 5.

Acquired Biological
Samples

CE-LIF Separation of
Pr-SSG

Statistical Analysis

PCA

K-means Clustering
Gaussian Distribution

Prediction of Mw

Classification Accuracy
Probability

Figure 5: A schematic block diagram describing overall experimental procedure.

The Statistical Pattern Recognition Toolbox (STPRtool) in Matlab was used in
this study [62]. The electrophoretic data was transformed into a set of uncorrected PCs.
These PCs were ranked according to each of their contributions based on the data
variance; data complexity was then reduced by eliminating redundant, orthogonal, and
independent PCs. The electrophoretic data from six groups (consisting of different
genotype and age) contain many features that are difficult to directly visualize and
capture. So, to classify the data samples into one of the six groups based on their
electrophoretic profiles, PCA was used to project the data onto PCs with large data
variances. The variance in each component is easily calculated by corresponded
eigenvalues divided by total eigenvalues. PCA score was used to inform us of the
cumulative variance of the data. Up to 80.10% of the total variance within the data can be
accounted for using three PCs. Every electropherogram has 3600 data points which are
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migration time points with their corresponding fluorescence intensity values and each
data point was treated as an independent variable. A PC was considered significant when
the contribution to total variances was greater than 1%. Each sample was analyzed in
triplicate and averaged to have the result in a single average electropherogram for the
individual sample. If the Mahalanobis distance of samples from the center of the score
plot was greater than the threshold, it was tagged as an outlier and eliminated from the
data set.
2.4.2

K-means Clustering Algorithm
K-means clustering algorithm [61, 62] was used to partition the data set in clusters

based on the genotype and age. A 5-fold cross-validation procedure [64] was used to
evaluate different classification tasks. Eighty percent (80%) of the data for each study
was randomly chosen to be the training set. The mean value of the training data set
belonging to the same group was computed in the three dimensional PC feature space.
The remaining 20% of the data was assigned to be the testing set. Each data point in the
testing set was assigned to the nearest known cluster. The classification accuracy was
defined to be the percentage of correctly identified testing data point. The data
randomization, clustering, and testing procedure were repeated five

times. Overall,

twelve classifiers were created (six using blood, and six using brain Pr-SSG data) as
outlined: (a) 3 - Genotype classifiers, one at the each age (1-month WT vs. Tg; 5-month
WT vs. Tg; 11-month WT vs. Tg). (b) 2 - Age classifiers, one for each genotype (WT: 1month vs. 5-month vs. 11-month; Tg: 1-month vs. 5-month vs. 11-month), (c) 1 Combination genotype and age classifier (1-month WT vs. 1-month Tg vs. 5-month WT
vs. 5-month TG vs. 11-month WT vs. 11-month Tg).
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2.4.3

Probability of Gaussian Distribution
A Leave-One-Out cross-validation method [65] was used to test the probability of

membership of each data point to each genotype and age.

A multivariate Gaussian

probability density function was used,

N(*h £)=

( 2 J ) o/2

j £ |,/2

e x pj~

^(*~

{ (x - //)j

Eq. 1

where x indicates each data point vector, /j. represents the mean vector, and £ is the
covariance matrix (a positive-definite and symmetric matrix). The output vector is the
probability density function between Gaussians. The probability of membership for the
each point x was obtained by adding the six probabilities (from the six groups) and
normalizing it to give a sum of 1. The probability of membership represents the
probability that the data point belongs to one of the Gaussians [62, 63]. The whole
procedure was repeated for brain tissues and blood samples.

CHAPTER 3

RESULTS

3.1
3.1.1

Glutathione Redox Status

Genotyping
Melting analysis of the PCR products generated with DNA from Tg showed a

decrease in the fluorescence of the double stranded DNA LCGreen dye (Data not shown).
When the melting curves were converted to melting peaks by plotting (-dF/dT vs. T), a
melting peak was observed with apparent Tm of 86.26 ± 0.6° C, which is the Tm specific
for APP gene. Since no APP transgenic genes existed in WT individuals, no APP gene
was amplified and gave rise to a flat melting curve with no fluorescence intensity.
Moreover, no single melting peak was observed in the converted -dF/dT vs. T plot.
Hence, this assay could easily distinguish AD transgenic mice from WT individuals.
3.1.2

Brain Weight
The wet weight of all mouse brain samples of each anatomic position (cerebrum,

cerebellum and hippocampus) in AD-Tg/WT mice at 3 age stages were measured before
tissue homogenization. The overall mean brain weights were 0.52 ± 0.02 and 0.51 ± 0.02
g, 0.50 ± 0.01 and 0.56 ± 0.01 g, 0.49 ± 0.03 and 0.41 ± 0.01 g for Tg and WT mice at 1-,
3-, and 11-month-old, respectively. One-way ANOVA for total brain weights of wild
type mice showed a significant age effect (P < 0.005). Compared to the 5-month-old,
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total brain weight of WT mice lost 7.64% at 11-month as indicated in Figure 6.
Moreover, the total mouse brain weight exhibited genotype difference between Tg and
WT for 5- and 11-month-old (P < 0.001); higher brain weight was observed in WT at 5month-old, whereas increased brain weight was shown in Tg at 11-month-old. Also, at 5month-old, WT has significantly lower cerebrum weight than its Tg counterpart (P =
0.03).
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Figure 6: Comparison of wet brain weight in cerebrum, cerebellum, hippocampus, and
total weight of AD-Tg/WT mice at 3 age stages. Data are presented as means ± SEM for
30 animals. Age effect: 1-month vs. 5-month vs. 11-month. +++ P < 0.001. Genotype
effect: Tg vs. WT. * P < 0.05. Tissue effect: hippocampus vs. cerebrum vs. cerebellum,
tt P <0.01, fft P< 0.001.
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3.1.3

Tissue Glutathione Status
HPLC was used to measure the level of GSH and GSSG in three anatomic

positions of brain tissue of AD-Tg/WT mice at 1-, 5- 11-month. The GSH/GSSG ratio
was calculated from these quantitative measurements. The results are shown in Figure 7.
The GSH content of AD-Tg mice in the cerebrum at 1-month was the highest, and the
levels decreased 17% and 40% at 5-, and 11-month, respectively (P = 0.03). On the
contrary, age-matched wild type mice had significant increases in the GSH amount in
cerebellum with age; 42% and 78% increases at 5-month and 11-month, respectively,
with respect to 1 -month-old mice (P = 0.03).
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Figure 7: Glutathione (GSH) and oxidized glutathione (GSSG) levels and GSH/GSSG
ratio in 1-, 5- and 11-month-old Tg and WT specific brain regions. Both (A) GSH and
(B) GSSG levels were determined by reverse-phase high performance liquid
chromatography (HPLC) following derivatization of samples with l-fluoro-2, 4dinitrobenzene (FDNB) as described in Methods; and (C) calculated GSH/GSSG ratio.
GSH and GSSG are expressed as nmol/mg proteins and presented as means ± SEM
(n=5/group). Age effect: 1-month vs. 5-month vs. 11-month. + P < 0.05, ++ P < 0.01.
Genotype effect: Tg vs. WT. * P < 0.05. Tissue effect: hippocampus vs. cerebrum vs.
cerebellum, f P < 0.05, ft P < 0.01, ttt P < 0.001.

As shown in Figure 7B, there was a significant decrease of 45% in GSSG
production in hippocampus at 5-month-old Tg compared with 1-month-old young mice
(P = 0.01). However, a 69% increase in GSSG level from 5-month-old to 11-month-old

26

(P = 0.01) was observed. Similarly, in Tg cerebrum, a significant decrease of GSSG from
0.29 to 0.09 nmol/mg protein was observed from 1-month to 5-month-old, followed by a
rise to 0.12 nmol/mg protein at 11-month-old (P = 0.009). In particular, there was a
decline of 46%, 45% and 39% of the GSH/GSSG ratio in the cerebrum, the cerebellum
and the hippocampus, respectively, in aged transgenic animals at 11 -month-old compared
with the 5-month-old mice. Additionally, the aging effect on GSSG was observed in WT
mice. Specifically, one-way ANOVA for GSSG level of WT type showed a 63% and
56% significant increase from 5-month-old to 11-month-old in the cerebrum (P = 0.02)
and in the cerebellum (P < 0.01), respectively.
The results in Figure 7 further revealed significant genotype differences in the
GSH redox status between Tg and WT mice. The Tg cerebrum exhibited a GSH value of
0.38 nmol/mg of protein, which is 20% less than its WT counterpart (P=0.03). Also, GSH
content was increased by 64% in 11-month-old WT mouse cerebellum than the Tg
counterpart (P=0.04). Genotypic differences in GSSG levels were evident in 1-month-old
(P = 0.02) and 5-month-old (P = 0.03) cerebrum. Specifically, significant GSSG
increases of 90% and 44% in Tg and WT were observed at these two stages.
In terms of brain regions, a significant difference in GSH content was observed
for AD-Tg mice at 1-month-old. In young mice, the highest baseline level of GSH was
seen in the cerebellum and the lower values in the hippocampus and cerebrum. This trend
generally continued in aged mice. Regarding GSSG variation in different brain regions,
the cerebrum exhibited decreases of 59% and 62% than cerebellum for 5-month Tg (P =
0.004) and at 11-month Tg (P < 0.001), respectively. For WT, significant decreases of
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62% and 61% in GSSG in the cerebrum than in the cerebellum were observed for 5month-old (P = 0.01) and at 11-month-old (P < 0.001), respectively.
One-way ANOVA for blood GSH level in Tg mice (Table 2) showed a significant
increase of 1.6 fold in 11-month-old compared with 1-month-old (P <0.005). Moreover,
significant age effect was observed in GSSG levels between 1-month and 11-month, with
an increase of 37% with aging (P<0.005). Blood GSH level in Tg mice at 1-month is
50% less than its WT counterpart (P=0.05). It is notable that both GSH and GSSG levels
in the blood were significantly higher than in brain tissues regardless of genotype. For
example, basal GSH level in the blood of 11-month-old Tg, 8.39 nmol/mg protein (Table
2) was 20-fold higher than that in the hippocampus (0.47 nmol/mg protein) at the same
age group (Figure 7A).
3.1.4

Blood Glutathione Status
One-way ANOVA for blood GSH level in Tg mice (Table 2) showed a significant

increase of 1.6 fold in 11-month-old compared with 1-month-old (P <0.005). Moreover,
significant age effect was observed in GSSG levels between 1-month and 11-month, with
an increase of 37% with aging (P<0.005). Blood GSH level in Tg mice at 1-month is
50% less than its WT counterpart (P=0.05). It is notable that both GSH and GSSG levels
in the blood were significantly higher than in brain tissues regardless of genotype. For
example, basal GSH level in the blood of 11-month-old Tg, 8.39 nmol/mg protein (Table
2) was 20-fold higher than that in the hippocampus (0.47 nmol/mg protein) at the same
age group (Figure 7A).
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Table 2: Blood glutathione status.

WT

Tg
Blood

1-mo. (n=5)

5-mo. (n=5)

11-mo. (n=5)

1-mo. (n=5)

5-mo. (n=5)

11-mo. (n=5)

GSH

3.19 ± 1.17 ++*

8.27 ± 0.65

8.39 ± 1.07

6.24 ± 0.75

8.61 ±0.85

9.08 ± 1.71

GSSG

7.01 ± 1.90

15.99± 1.36

18.25 ±2.35

12.40 ±0.49

16.21 ±2.55

18.75 ±7.95

0.52 ± 0.03

0.46 ±0.03

0.50 ± 0.04

0.53 ± 0.07

0.48 ± 0.04

GSH/GSSG

0.45 ±0.14

GSH and GSSG levels are expressed in nmol/ml and presented as means ± SEM with the
number of mice per group indicated in parenthesis. Age effect: 1-month vs. 5-month vs.
11-month. ++ P < 0.01. Genotype effect: Tg vs. WT. * P < 0.05.

3.1.5

Mixed-disulfide Status
Next, we examined protein glutathione levels. Significant age differences were

found in Pr-SSG contents at all 3 age stages in Tg-cerebrum (P = 0.03), Tg-cerebellum (P
= 0.04), and Tg-blood (P = 0.04) with increases of Pr-SSG levels from 1-month to 11month-old (Figure 8). Also, 5-month-old animals exhibited significant decreases of 1.5and 5.4- and 4.8-fold in Pr-SSG levels in these brain regions and blood, respectively,
when compared with 1-month-old. Similar to what was observed in GSSG fluctuations
with aging in Tg mice (see Figure 7B), we observed a dip in GSSG levels at 5-month-old
rather than a steady increase in Pr-SSG with aging.
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No Pr-SSG was detected at 1-month-old mice in WT brain tissues except in the
hippocampus, whereas high Pr-SSG levels were found in Tg brain tissues at this early
stage. As shown in Figure 8, the levels of Pr-SSG in Tg-cerebrum were 1.6- and 8-fold
higher than its WT counterparts at 5-month (P=0.006) and 11-month (P=0.01),
respectively. Additionally, the cerebellum showed a significant genotype effect at 1month (P=0.03) and 11-month (P=0.04).
No significant tissue effect was seen in the different Tg brain regions, but
differences between the hippocampus and other brain regions were observed in WT mice
at 1-month (P=0.005) and at 11-month (P=0.04). As compared to WT-cerebrum and
cerebellum, the hippocampus was the only region that started to show the detectable
levels of Pr-SSG at 1-month-old. At 11-month-old, hippocampal Pr-SSG in WT was 27%
higher than cerebellum. These findings support the notion that increased formation of PrSSG contributes to the specific vulnerability of the hippocampal zone of the AD brain.
3.1.6

Enzymatic Activity
Because of the observed changes in glutahione redox (Figures 7 and 8), we also

examined the two key enzymes of the glutathione redox cycle: GPx converts GSH to
GSSG in the presence of hydroperoxides, GR catalyzes the conversion of GSSG to GSH
with a cofactor, NADPH. Statistical analysis of GR and GPx activities was done by one
way ANOVA shown in Figure 9. The results indicate no age or genotyping difference in
GR activity. Also, no genotyping effect was observed in GPx. However, GPx activity
shows significant increase in aging for both AD-Tg (P<0.001) and WT mice (P=0.01). In
specific, comparing the two age stages (1-mo. v.s. 24-mo.), GPx activity increased from
24.7 to 43.5 nmol/min/ml in AD-Tg and from 26.1 to 43.5 nmol/min/ml in WT brain. The
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relative higher increase in GPx activity compared to GR activity suggests that glutathione
redox cycling might be compromised in the brain of older mice.
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Figure 9: Activities of glutathione reductase (GR) and glutathione peroxide (GPx) in ADTg/WT mouse brain at 1-, 5- and 24-month. Data are expressed as nmol/min/ml and
presented as means ± SEM. Age effect: 1-month vs. 5-month vs. 11-month. + P < 0.05,
++P<0.01.
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3.2
3.2.1

Oxidized Protein

Grx-catalyzed Deglutathionylation
Proteins were first heavily alkylated with NEM to block residual protein thiols

and then subjected to deglutathionylation to generate newly formed free thiols. The
ability to specifically identify and further reduce Pr-SSG is crucial for the selectivity of
this derivatization method. Grx belongs to the thiol-disulfide oxidoreductase family [66].
Grx catalyze the reversible reduction of the Pr-SSG to free SH group though a monothiol
mechanism by relying solely on the N-terminal Cys22 [57, 67, 68]. Cys 22 residue of Grx
will become S-glutathionylated itself. The reduced form of Grx can then be regenerated
using GSH coupled to GSSG reductase [68]. Since native Grx can recognize protein
disulfides and reduce them also, it potentially produces false positive artifacts [69]. So we
elected to utilize the mutant enzyme CHS, C65Y of gluaredoxin-3 (Grx-3) mainly due to
its preference for the reduction of protein bound S-glutathiols [70]. The selectivity of this
reductive treatment was also demonstrated in a Pr-SSG proteomic study [44], It was
noted by Mannervik that at least 0.5 mM GSH is required to ensure optimal activity of
Grx [71]. We followed the optimal concentrations of all enzymes involved in
deglutathionylation cycling [58].
3.2.2

Detection and Validation
In the present work we provide a novel approach for monitoring S-

glutathionylated proteins based on the selective enzymatic recognition of Pr-SSG,
fluorescent labeling and quantification by CGE-LIF analysis. To validate the analytical
system, we chose to analyze in vitro oxidized BSA. As stated in the method section,
various controls including (a) Dylight 488 maleimide dye alone; (b) BSA-SSG without
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Grx-3 catalyzed deglutathionylation step; (c) BSA-SSG pretreated with DTT to reduce
the protein bound disulfides; (d) native BSA without S-glutathionylation were performed
to validate the detection of S-glutathionylation using this method.
Firstly, we studied the CGE-LIF analysis of the fluorescent dye, Dylight 488
maleimide. This analysis is to differentiate the peaks of dye itself from those of Sglutathionylated proteins and further identify how differently they distribute in terms of
migration time. Trace 1 in Figure 10 demonstrated that the Dylight 488 maleimide alone
shows multiple peaks occurring between 347 and 573 s, whereas in vitro Sglutathionylated BSA (trace 2 in Figure 10) exhibits a new additional peak appearing at
796 s, indicating the detection of S-glutathiols. Altogether, it validated the reactivity of
Dylight 488 maleimide toward the disulfide group in the treated BSA.
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Figure 10: In vitro S-glutathionylated bovine serum albumin (BSA-SSG) and validation
of the method using controls. (1) Electropherograms of Dylight 488 maleimide; (2)
BSA-SSG; (3) BSA-SSG without glutaredoxin (Grx) reduction; (4) BSA-SSG pretreated
with dithiothreitol (DTT); (5) native BSA. Hydrodynamic injection at pH 8 and 11 kpa
for 4 s; separation in gel containing 15% dextran (64-76 kDa), 0.5% SDS, 20 mM Tris
and 20 mM Tricine at -570 V/cm. 1 & 2 indicate Dylight 488 maleimide. Top trace is
offset in the y-axis for the clarity.

Secondly, a control experiment was performed in the presence of all the
derivatization steps except Grx deglutathionylation, and no peak at 796 sec for the BSASSG was observed (Trace 3 in Figure 10). Grx mediated deglutathionylation is essential
to enzymatically reduce S-glutathionyls and further generate newly generated free thiols
for consecutive labeling. Thus, the omission of the deglutathionylation step and no Sglutathionyl detection in this negative control further validates the requirement of the
enzymatic cycling for the labeling reaction.
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Furthermore, the selectivity of S-glutathionyls labeling was also exploited in
native BSA and BSA-SSG pretreated with reducing agent, DTT. After the DTT
treatment, the protein-bound S-glutathionyls was reduced and hence the consecutive
labeling of S-glutathionyls was abolished. In native BSA, no S-glutathiols are available
for labeling. As we expected, in both controls, no peak around 796 s was observed in
both traces 4 and 5 of Figure 10. All these observations further indicate the selectivity of
this method.
Dylight 488 fluorophore tagged Pr-SSG will lead to an increase in molecular
weight (Mw). The addition of NEM (124 Da), reduction of S-glutathionyls (-307 Da) and
maleimide labeling (800 Da) will result in an increase of Mw of 617 Da. Proteomic study
disclosed that the majority of identified S-glutathionylated proteins have Mw ranging
from 25 to 70 kDa [44]. Therefore, the Mw shift of 617 Da is insignificant compared
with the S-glutathionylated protein size itself, and this derivatization procedure will have
little effect on the protein mobility in the CGE separation.
3.2.3

Evaluation of NEM Removal
After alkylating the free thiols, the NEM was removed using Amicon Amicon

ultra-4 (Mw cutoff of 3000 Da) spin columns. If the removal were not complete, the
remaining NEM will compete with Dylight 488 maleimide by reacting with freshly
reduced thiols from S-glutathionyls. This would cause a decrease or no signals for the
detection of S-glutathionylated proteins. Therefore, we investigated whether the levels of
NEM removal were associated with the numbers of ultracentrifugation washes. Figure 11
displays a peak at approximately 796 s representing BSA-SSG after six washes with
desalting column, whereas no peak detected for S-glutathionyl after only three washes.
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This observation indicated that by doubling the desalting wash times, the excess NEM
was completely removed, which eliminated its interference of binding reduced Sglutathionyls.
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Figure 11: Comparison of desalting efficiency using spin columns at different times.
Completely removing blocking reagents is crucial in this experiment. Remaining Nethylmaleimide (NEM) can cause unnecessary blocking to freshly formed thiol groups.
Double the desalting times will solve this problem. Top trace shows clear peaks for
maleimide and S-glutathionylated bovine serum albumin (BSA-SSG) (1 and 2 indicate
Dylight 488 maleimide using spin columns for 6 times). Bottom trace shows no peak for
BSA-SSG (F and 2' indicate Dylight 488 maleimide using spin columns for 3 times).
All the experimental conditions are the same as in Figure 10. Top trace is offset in the yaxis for the clarity.
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3.2.4

Assessment of Blocking Efficiency
The derivatization procedure only works when only S-glutathionylated cysteine

residue will be derivatized and fluorescently labeled. If the free thiols were not
completely blocked with NEM, then the remaining nonblocked cysteines would be
labeled with Dylight 488 maleimide and produce a false artifact in the electropherogram.
Hence, we studied the blocking efficiency using various concentrations (10, 30 and 40
mM) of two blocking reagents, NEM and IAA without deglutathionylation step. As seen
in Figure 12, 40 mM of NEM was considered as the optimal concentration to completely
block all the free thiols in BSA-SSG.
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Figure 12: Comparison of blocking efficiency between Iodoacetic acid (IAA) and Nethylmaleimide (NEM) at three concentration conditions. S-glutathionylated bovine
serum albumin (BSA-SSG) samples were reacted with IAA and NEM, respectively. Top
3 traces indicate 10, 30 and 40 mM IAA with solid lines. Bottom 3 traces indicate 10, 30
and 40 mM NEM. 1 & 2 indicate Dylight 488 maleimide. All the experimental conditions
are the same as in Figure 10. Top trace is offset in the y-axis for the clarity.

3.2.5

Assay Reproducibility and Accuracy
The concentration of S-glutathionyl groups in S-glutathionylated BSA was

determined by Ellman's colorimetric assay, which was expressed as 92.41 nmol Sglutathionyl per 1 mg BSA protein. Therefore, the concentrations of a serial dilution (1-,
1.3-, 2-, 4-fold and 10-fold dilution) of BSA-SSG were calculated ranging from 92.41 to
9.24 nmol/mg protein. In Ellman's assay, immobilized TCEP was used because: (1) It
allows recovering reduced BSA in high yield without dialyzing or desalting steps; (2) It
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eliminates the possibility of the remaining TCEP reacting with Ellman's reagent, DTNB;
(3) it does not interfere with consecutive thiols-reactive reagent, i.e. maleimide
crosslinkers. The calibration curve was generated by separately injecting a serial dilution
of S-glutathionylated BSA in triplicate onto CE (Figure 13). The integrated fluorescence
peak area and corresponding S-glutathiol (in moles) are indicated as y and x in the
calibration curve, respectively [72].
>> = (5 + 0.12)x 10l5x-(2.28±3);

R2 =0.996

Eq. 2

LOD and LOQ are defined as the amount for which the S/N is 3 and 10,
respectively. In this CGE-LIF study, the LOD and LOQ of S-glutathionyl groups assessed
by Equation 2 were 1.8 and 6 attomole, respectively, which are the lowest LOD and LOQ
reported to date.
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Figure 13: Electropherograms of a series of dilution (1-, 1.3-, 2-, 4-fold) of Sglutathionylated bovine serum albumin (BSA-SSG)labeled with Dylight 488 maleimide.
1 & 2: Dylight 488 maleimide. All the experimental conditions are the same as in Figure
10. Top trace is offset in the y-axis for the clarity.

The reproducibility of the method was determined by performing three replicate
injections of the in vitro S-glutathionylated BSA solution. The RSD values for migration
time and peak area were 2.0% and 0.5%, respectively, suggesting good reproducibility in
the measurement of S-glutathionylation abundance in one sample. The precision of the
method was determined by replicate injection of the test model, in vitro Sglutathionylated BSA on three consecutive days. The RSD values of migration time and
peak area were 5.5% and 0.7%, respectively, for the day-to-day precision assay. The
accuracy was determined by performing a standard spiking method, where known
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amounts of S-glutathionylated BSA (BSA-SSG) standard was mixed with previously
analyzed BSA-SSG and further detected by CGE-LIF method in triplicates. The
concentration of BSA-SSG was subsequently quantified by the calibration curve. The
percentage of the spiked BSA-SSG analyte recovered by the assay indicates that the
accuracy of the method was 93.5%.
3.2.6

S-glutathionylation Determination
To illustrate the potential of this novel analytical method, we directly applied it to

the analysis of MQ-induced S-glutathionylation. Figure 14a (traces 1 and 2) demonstrates
wide peaks (738s - 1103s), indicating a broad range of proteins susceptible to Sglutathionylation in this oxidative stress cell model. A negative control carried by
eliminating the Grx-catalyzed deglutathionylation (shown in trace 3 of Figure 14a) also
highlighted the specificity of this derivatization method and the necessity of this
reduction step.
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Figure 14: Quantitative electrophoretic profiling of menadione (MQ) mediated Sglutathionylation (Pr-SSG) in human colon adenocarcinoma (HT-29) cells and Pr-SSG of
brain tissues and blood in AD-Tg/WT mice, (a) Electropherograms of Pr-SSG from HT29 cells labeled with Dylight 488 maleimide. Trace 1 demonstrates Pr-SSG from MQ
treated HT-29 cells. Traces 2 and 3 indicate MQ untreated HT-29 cells and MQ treated
HT-29 cells without deglutathionylation, respectively, (b) Electropherograms of Pr-SSG
in cerebrum of AD-Tg/WT mice at 5-month, (c) Electropherograms of Pr-SSG from 3
anatomical positions (cerebrum, cerebellum and hippocampus) in brain tissue and blood
sample of AD-Tg mouse, (d) Electropherograms of Pr-SSG from 3 anatomic brain
regions and blood of AD-WT mouse. 1 & 2: Dylight 488 maleimide. All the experimental
conditions are the same as in Figure 10. Top trace is offset in the y-axis for the clarity.

Based on the Equation 2, and the measured peak area for the S-glutathionylated
peaks, the total S-glutathionyls content in the injected volume for MQ-treated and
untreated HT-29 cells were calculated as (326 ± 15) fmol (average ± SD; n=3) and (41 ±
3.4) fmol, (average ± SD; n=3), respectively. For the CE analysis, only 1.1 nL volumes of
samples were hydrodynamically injected, which leads to 1.41 ng and 1.40 ng of total
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proteins for the MQ treated and untreated cells, respectively. Therefore, the treatment
with MQ resulted in 8-fold increase in protein-bound S'-glutathionyls contents (232 ±
10.6 nmol/mg protein) compared with untreated cells (29.3 ± 2.5 nmol/mg protein). MQ,
a redox cycling quinine can form the toxic species, the semiquinone (SQ ) radical through
the one-electron metabolism catalyzed by NADPH-ubiquinone oxidoreductase (ubQO).
Also, MQ can be replenished by reaction between SQ- and O2 with concomitant free
radical generation of superoxide anion (O2 ~) [45], Our results are in close agreement with
other reported values for Pr-SSG in this MQ mediated oxidative stress model [45]. In
addition, the relative standard deviation (RSD) was 4-7% indicative of reproducibility of
LIF detection of Dylight 488 labeled S'-glutathionyls in multiple CE injections.
3.2.7

Monitoring Pr-SSG in Mice Brain
Another direct biological application of this CGE-LIF method was demonstrated

in characterizing the electrophoretic profiles in nanogram (ng) amounts of whole blood
and brain tissues including the hippocampus, the cerebrum and the cerebellum from 5month-old AD-Tg mice. The fluorescence of Dylight 488 maleimide-labeled S'glutathionyls was detected in a migration window between 725 and 927 s in both Tg and
WT mice (Figure 14c and 14d). The quantitative amounts of Pr-SSG in different
biological samples were calculated and listed in Table 3. To further improve separation of
protein mixture based on size, an additional experiment for gel condition test was
performed by detection of Pr-SSG in the cerebrum of AD-Tg/WT mice at 5-month old
using gel matrix containing 10% dextran (Mw: 64-76 KDa), 0.5% SDS, 20 mM Tris, and
20 mM Tricine. The only difference between original (15% dextran) and this new
experiment (10% dextran) is gel percentage, where the same Mw dextran was used. The
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result is shown in Figure 15, which indicates gel percentages affect the Pr-SSG separation
efficiency. To obtain further optimum resolution, gel concentration and 2D-CE will be
investigated in a future study.
Table 3: S-glutathionyl contents.

Sample Sources
Cerebrum
Cerebellum
Hippocampus
Whole blood

AD-Tg Mice
10.38 ±4.51 (nmol/mg)
3.31 ± 0.96 (nmol/mg)
1.36 ± 0.11 (nmol/mg)
16.3 ±2.25 OiM)

WT mice
11.99 ± 4.29 (nmol/mg)
1.06 ± 0.13 (nmol/mg)
3.37 ± 0.58 (nmol/mg)
27.4 ± 2.96 (nM)

The B6.Cg mice model is associated with early onset of AD so that it was selected
for the study of neurodegenerative alternation, S-glutathionylation, with the AD
progression. Mice genotyping was accomplished with melting curve analysis and the
results are shown in Figure 16. Since the appearance of amyloid pathology and cognitive
impairment are generated in transgenic mice at 6, 7-month of age, it is intriguing for us to
study 5-month-old mice pair and explore whether S-glutathionylation formation precedes
the appearance of amyloid plaque. We demonstrated the feasibility of applying this newly
developed CE-LIF method to detect and quantify S-glutathionylated proteins in whole
blood and specific brain regions including the hippocampus, the cerebrum and the
cerebellum from a 5-month-old AD mice pair (data shown in Table 3). Although no
statistical evaluation regarding genotyping can be undertaken in this initial animal study,
this method proves to be a valuable tool for future investigation into characterizing Sglutathionylation abundance and electrophoretic profile with AD progression. To further
understand the cause of early onset AD, a large scale animal study including AD-Tg/WT
mice pair at different age stages such as 1-, 5-, and 11-month-old, indicative of long
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before, immediately before and long after amyloid plaque accumulation, is necessary for
examining whether S-glutathionylation formation is an early event in the AD progression.
Additionally, we envision that this method can serve as a platform for study disease
etiology and serve as prescreening of AD if different S-glutathionylation patterns indeed
occur with progression.
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Figure 15: Gel condition test for S-glutathionylated protein (Pr-SSG) in cerebrum of ADTg/WT mice at 5-month old using gel matrix containing 10% dextran (Mw: 64-76KDa),
0.5% SDS, 20 mM Tris and 20 mM Tricine. 1: Dylight 488 maleimide. All the
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the clarity.
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Figure 16: Melting curves (A) and melting peaks (B) of App gene. Melting temperature
(Tm) of App gene is 86.0 ± 0.6 °C (peak area=l 8).

The quantitative data listed S-glutathionylated protein levels in specific brain
regions. Previous studies reported that the levels of reduced GSH in 4-month-old mouse
brain varied in different anatomical positions, with cortex > cerebellum > hippocampus
[73, 74], However, in another rat study, no brain region associated the difference in Sglutathionyl expression was observed [75]. The discrepancy might be due to the use of
different species. Currently, our data is not conclusive to discuss whether Sglutathionylation level varies with brain regions with AD progression. However, this new
method has explicitly displayed the potential to lead a complete study to answer the
biological question, such as whether regional vulnerability of the AD brain tissue is
reflected in differences in S-glutathionylated protein pattern.
The results demonstrated the extent of protein S-glutathionylation in whole blood,
averaging 16.3 |iM, which is equal to 7.15 nmol/mg protein. The level of Pr-SSG in
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human blood was reported as 138 uM [14]. The discrepancy between the two values
might be due to the differences of species [14].

Blood protein-bound glutathione

concentration may reflect glutathione status in other less readily accessible tissues, such
as brain biopsy, thus of blood measurement has been considered as an index for of whole
body oxidative stress status, and serves as an important biomarkers diagnostically [76].
Altogether, with Mw pattern distribution characterized from the CGE separation, we
envision that the method can be further extended to investigate the S'-glutathionyls
patterns classification in blood samples from the involvement of AD disease progression
using chemometric tools such as principal component analysis. If difference in
electrophoretic profiles exists, this method could potentially become a pre-screening tool
for early detection of AD.
Our method of coupling Grx-catalyzed derivatization and labeling of protein
bound S-glutathionyls to CGE-LIF detection has exhibited several great merits, including
low LOD, fast analysis time (within 15 min) and potential for Mw pattern classification.
It reached the limit of S-glutathionyls detection of 1.8 attomole, which is 109 fold less
than the conventional Ellman's assay [77] and significantly faster than traditional SDSPAGE analysis which might take up to 2 days. It may facilitate the glutathione
homeostasis study in minuscule biological samples, such as single cells or biopsy tissues.
3.2.8

Pr-SSG in Protein Profiles
We previously developed an ultrasensitive CGE-LIF method for the detection and

quantification of S'-glutathionyl, reaching the lowest limit of Pr-SSG detection at 1.8
attomole level, reported to date [78]. Here, we used this analytical method to quantify S-
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glutathionyl abundance in brain and blood preparations obtained from 5 pairs of ADTg/WT mice at the three age stages (10 animals/age group, total of 30 animals).
After calibration, each biological sample was analyzed in triplicate. Based on
Equation 2 and the measured peak area for S-glutathionylated peaks, the total Sglutathionyl content (in fmol) for each injected protein sample preparation (in ng) was
calculated. The results in Figure 17e and 17f suggest that S-glutathionyl levels of Tg mice
brains increased with aging (PO.OOl) except at the 5-month-old, and Pr-SSG levels at 1-,
5- and 11-month-olds were 43.0 ± 7.2, 36.6 ± 7.0 and 129.8 ± 14.2 nmol/mg protein,
respectively. No significant change with aging was observed in the WT mouse brain. For
the genotype effect, there is a significant increase in S-glutathionylation abundance in Tg
brain tissues compared with controls' at the 1-month (P<0.05) and 11-month-olds
(P<0.001). For blood samples, Pr-SSG contents increased with aging for both control and
Tg mice (PO.OOl). Specifically at the three AD staging, Pr-SSG levels were measured as
10.6 ± 1.0, 18.0 ± 1.3 and 32.1 ± 4.1 nmol/mg protein, respectively, whereas Tg
counterparts had Pr-SSG levels of 10.7 ± 2.5, 33.3 ± 7.1 and 46.9 ±11.4 nmol/mg
protein, respectively. In terms of the genotype effect, blood Pr-SSG abundance in Tg
mice at 5-month (P<0.01) and 11-month-olds (P<0.5) was significantly higher than their
age-matched control mice. These results are in agreement with the results of previous
studied [78]. All Pr-SSG values are expressed as mean ± standard deviation (S.D.).
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3.2.9

Principal Component Analysis
Due to the nature of CE separation, this electrophoretic method also produces a

protein molecular weight (Mw) based profile of S-glutathionylated proteins. These
complex data matrices are desirable for powerful multivariate analysis. The primary
research objectives are used to assess whether reactive oxygen species (ROS) induced
protein oxidative stress such as S-glutathionylated proteins distribution as a function of
Mw (1) differs between AD and control subjects; and (2) exhibits different features at
different stages of AD progression. We evaluated the utility of the combination of S'glutathionyls profiling and PCA analysis for AD diagnosis. Particular attention was paid
to the number of PCs, as they are viewed as a critical factor to determine the outcome of
the PCA model. As seen in Table 4, the first three PCs from brain tissues and blood
samples, account for up to 80.10% and 82.37% of the total variance in six age/genotype
groups, respectively. Figure 18 shows that the brain and blood in the six age/genotype
groups were distinguished by principal component scores. Since it can sometimes be
difficult to appreciate the degree to which these individual groups are separated in a
three-dimensional plot, we have also prepared a two-dimensional score plot for each
genotype-WT and Tg shown in Figure 19.
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Table 4: PCA variance in brain tissues and blood samples.

3.2.10

Brain
PCI

Variance
53.22%

Cumulative
variance
53.20%

Blood
PCI

Variance
56.84%

Cumulative variance
56.84%

PC2

20.71%

73.90%

PC2

16.53%

73.37%

PC3

6.56%

80.10%

PC3

9.00%

82.37%

PC4

5.17%

85.20%

PC4

6.06%

88.43%

PC5

4.59%

89.80%

PC5

3.07%

91.51%

PC6

2.15%

92.40%

PC6

1.80%

93.31%

Prediction of Molecular Weight
PCA can be utilized to evaluate the "importance" of variables, such as protein

Mw values converted from the migration time (see Figure 4 for details) by examining
loading vectors of PCs. The contribution of protein Mw to this PCA model was evaluated
by inspecting the loading vector of the first PC shown in Figure 20. The first PC accounts
for 53.22% of the total variance in Table 4. The contribution of any given Mw value to
the total variance was determined by the loading vector value: the higher loading vector
value indicates the bigger contribution of the corresponding Mw. Arbitrarily, 50% of the
loading vector maximum (0.03/dashed line) was set as the threshold to inspect which
regions were considered as the most contributors to this model variance. The main Mw
regions in mice brains are found at 1.4 kDa and 8.4-20.3 kDa. For blood samples, the
Mw ranges are located at 8.3 kDa and 13.2-37.2 kDa. The first region is associated with
small, non-protein fluorescent species present in the sample. The second region predicts
the Mw range where the most age-related and genotype-related S-glutathionylations
occur.
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3.2.11

Sample Categorization
Classification of the each sample data into one of six groups based on its

electropherogram profile feature was achieved using a K-means clustering method. The
boxplots of classification accuracy based on a 5-fold cross-validation method are shown
in Figure 21. The binary classifiers for the discrimination of genotype at the three age
groups are shown in Figure 21a and 21b. The accuracies of distinguishing the WT versus
Tg genotype at the three age stages of brain/blood samples were found to range from
70.00% to 100.00%, with sufficient discrimination power. Regardless of the data sample
type, at 5-month, the classification accuracy was always the lowest with half the data
samples testing no better than chance classification. At 1-month and 11-month-olds, most
data can be correctly classified to be either WT or Tg genotype. Next, the age of the Tg
and WT mice can be distinguished better than chance as seen in Figure 21c, with
accuracies ranging from 93%-100% and 66.67%-73.34% for brain tissues and blood
samples, respectively. Figure 21d shows the combined age/genotype classification
results. An overall classification accuracy of 70.02% can be achieved using brains and
60.00% using blood samples. So, the disease progression stage contributed significantly
to group separation for both AD and controls, while genotyping contributed very largely
to group separation at 1- and 11-month-olds, except at 5-month old, right before the
amyloid deposition.
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A leave-one-out validation method was also applied to test the classification
accuracy for the age and genotype. To classify samples into one of six groups based on
their S-glutathionylation profiles, six disjoint PCA models were used for pattern
recognition and sample classification. The normalized Gaussian distribution probabilities
of membership using S-glutathionylated protein electrophoretic profiling data of both
brain tissues and blood samples were computed. Table 5 showed the final results using
brain data, with 28 correct assignments out of 30 samples (>95% confidence). The
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difference between AD and control at the three disease progression stages in the brain can
be separated out even further, thus obtaining the correct classification. Using the blood
data from Table 6, however, only 13 out of 30 samples were assigned correctly with
>95% confidence. Despite the seemingly low accuracy level using blood samples, this
result is still more than twice as high as the random classifier. It is probably more
appropriate in single-trial classification applications where a new brain or blood sample is
compared with Gaussian clusters obtained from an existing data base of existing AD v.s.
non-AD samples.
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Table 5: Probability of membership in the six age/genotype group—brain.

Sample

1-mo. Tg

1 -mo. WT

5-mo. Tg

5-mo. WT

11-mo. Tg

11-mo. WT

1-mo. Tgl

1.00

3.15E-13

1.56E-21

0

0

2.34E-28

1 -mo. Tg2

0.93

4.74E-08

0

0

0.07

0

1-mo. Tg3

1.00

6.69E-04

0

0

9.61 E-05

0

1-mo. Tg4

0.95

6.26E-16

0

0

0.05

0

1-mo. Tg5

1.00

0

9.57E-16

0

0

0

1-mo. WT1

4.21E-14

1.00

0

0

1.87E-03

0

1-mo. WT2

0

1.00

0

0

1.52E-23

0

1-mo. WT3

1.03E-16

1.00

0

0

1.85E-04

0

1-mo. WT4

0

1.00

3.50E-18

0

2.92E-12

2.36E-15

1-mo. WT5

7.49E-07

1.00

0

0

4.58E-04

1.07E-20

5-mo. Tgl

3.96E-03

0

0.37

0

0

0.63

5-mo. Tg2

0

1.36E-13

0.96

8.54E-14

0

0.04

5-mo. Tg3

0

0

1.00

2.55E-12

0

0

5-mo. Tg4

0

2.66E-2I

1.00

4.72E-09

0

2.86E-12

5-mo. Tg5

0

0

0.95

0.05

0

0

5-mo. WT1

0

0

0.02

0.98

0

0

5-mo. WT2

0

0

3.95E-15

1.00

0

3.93E-16

5-mo. WT3

0

0

3.51 E-06

1.00

0

0

5-mo. WT4

0

0

9.18E-15

1.00

0

0

5-mo. WT5

0

0

4.78E-12

1.00

0

0

11-mo, Tgl

0

1.05E-12

0

0

1.00

0

11-mo. Tg2

6.67E-20

0

0

0

1.00

0

11-mo. Tg3

0

0

0

0

1.00

0

11-mo. Tg4

0.04

0

0

0

0.96

0

11-mo. Tg5

0

0

0

0

1.00

0

11-mo. WT1

0

1.47E-03

5.07E-12

0

0

1.00

11-mo. WT2

7.17E-25

6.08E-05

1.83E-08

0

0

1.00

11-mo. WT3

9.69E-28

1.57E-04

3.01E-16

0

0

1.00

11-mo. WT4

2.59E-18

2.02E-17

2.67E-06

0

0

1.00

11-mo. WT5

0

1.77E-06

2.28E-04

0

0

1.00

Notes: Mo = Month; Tg = Transgenic; WT = Wild-type; The highest probability value in
the each row indicates that a sample belong to a particular class (boldface). The italic
numbers indicate the correct classification with confidence level above 95%.
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Table 6: Probability of membership in the six age/genotype group—blood.

1-mo. Tg

1-mo. WT

5-mo. Tg

5-mo. WT

11-mo. Tg

11-mo.WT

1-mo. Tgl

0.97

0.03

2.42E-08

1.07E-03

4.09E-06

7.72E-04

1-mo. Tg2

0.99

3.17E-11

5.73E-11

7.24E-04

3.76E-03

9.06E-04

1.40E-04

6.53E-04

Sample

1-mo. Tg3

1.00

1.48E-05

2.85E-08

7.59E-04

1-mo. Tg4

0.99

3.50E-10

2.07E-10

9.22E-04

3.82E-03

1.35E-03

1-mo. Tg5

0.98

8.69E-12

9.84E-07

2.06E-03

9.24E-03

4.06E-03

1-mo. WT1

0

1.00

8.02E-05

2.68E-03

3.22E-04

4.34E-07

1-mo. WT2

0.05

0.94

8.78E-06

3.58E-03

1.18E-08

1.53E-03

1-mo. WT3

0.02

0.98

1.90E-04

3.65E-03

3.76E-08

1.85E-03

1-mo. WT4

0

0.94

0.06

1.49E-03

8.21E-06

2.00E-07

1-mo. WT5

0

0.99

9.52E-03

3.93E-04

8.49E-07

1.26E-I0

5-mo. Tgl

1.46E-11

1.03E-28

0.23

0.09

0.32

0.35

5-mo. Tg2

0

0

1.00

2.14E-04

3.66E-04

5.43E-18

5-mo. Tg3

0

0

0.53

0.14

0

0.33

5-mo. Tg4

0

3.77E-25

0.24

2.24E-04

0.76

2.88E-15

5-mo. Tg5

0

0

0.98

0.02

0

3.12E-08

5-mo. WT1

2.10E-07

2.04E-15

0.22

0.14

0.32

0.32

5-mo. WT2

0

0

0.60

0.38

0

0.02

0.81

0

0.19

5-mo. WT3

0

0

1.41E-09

5-mo. WT4

0

0

0

0.98

0

0.02

5-mo. WT5

0

0

0

0.96

0

0.04

11-mo. Tgl

5.95E-08

1.48E-24

0.09

0.11

0.53

0.28

11-mo. Tg2

0

0

0

6.01E-12

1.00

0

11-mo. Tg3

0

3.94E-05

0.13

1.63E-03

0.87

3.54E-12

11-mo. Tg4

0

3.56E-15

0.24

6.28E-05

0.76

1.11E-16

11-mo. Tg5

0

3.87E-23

0.24

3.20E-03

0.76

6.12E-11

11-mo.WTl

1.19E-15

0

0.30

0.11

0.09

0.49

11-mo. WT2

0

0

0.03

0.11

3.20E-22

0.86

11-mo. WT3

0

0

0.01

0.31

1.12E-09

0.67

11-mo. WT4

0

0

0.41

0.10

0

0.49

11-mo. WT5

0

0

6.84E-20

0.38

5.56E-29

0.62

Notes: Mo = Month; Tg = Transgenic; WT = Wild-type; The highest probability value in
the each row indicates that a sample belong to a particular class (boldface). The italic
numbers indicate the correct classification with confidence level above 95%.

60

Finally, we performed a receiver operating characteristics (ROC) analysis for both
brain tissues and blood samples with only classifying AD and non-AD phenotypes,
without

taking disease progression staging into consideration. The 30 brain

electropherograms (5 pairs of AD and WT at each of three age stages) that were used to
differentiate AD and non-AD phenotypes reached 100.00% in both sensitivity and
specificity (as shown in Figure 22a). Also, Figure 22b suggests that the validation cohort
of the 30 blood electrophoretic profiles achieved high discrimination power, with
sensitivity of 93.33% and specificity of 90.00%. These preliminary results suggest that
PCA is a powerful method for multivariate analysis of complex data, such as
electropherograms describing S-glutathionyl profiles for the diagnosis of AD.
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respectively.
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3.3
We

developed

a

procedure

Damaged DNA
for

the

analysis of

8-OHdG

comprising

immnuoaffinity and indirect fluorescence labeling of 8-OHdG, their separation by CE,
and on-line detection by LIF. To monitor the damage to the DNA base guanine in
transgenic AD mice, we developed an assay that utilizes the very low sensitivity of the
capillary electrophoresis coupled with laser induced fluorescence detection. In addition,
this assay takes advantage of the specificity provided by the monoclonal antibody N45.1
to 8-OHdG. Simple manipulation comprises of urine centrifugation, incubation with the
antibody, and capillary electrophoresis separation.
3.3.1

Calibration Curve
To test the feasibility of the assay, we used N45.1 mouse monoclonal antibody

that is specific to 8-OHdG. First of all, capillary electrophoresis validated no presence of
impurities in primary antibody (Figure 23 trace 5). Next, it separated the unbound
secondary antibody at 135 s and 278 s (Figure 23 trace 4), and a complex of the
secondary antibody along with primary antibody (Figure 23 trace 3). In addition, a
complex of 8-OHdG (10 ng-|iL_1) with primary and the secondary antibodies was
analyzed for generating a calibration curve (Figure 23 trace 2). Furthermore, the 8-OHdG
complex (1000 ng-jiL"1) peak was determined in this study by comparison of the
migration time and spiking at 162 s. (Figure 23 trace 1).
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Figure 23: Electropherograms of validation tests in positive and negative controls. (1) a
complex with 1000 ng-^L"1 8-hydroxy-2'-deoxyguanosine (8-OHdG) standard; (2) a
complex with 10 ng jiL"' 8-OHdG standard; (3) a complex with primary and secondary
antibody; (4) secondary antibody alone; (5) primary antibody alone. Hydrodynamic
injection at pH 9.5 and 0.5 psi for 5 s; separation in 20mM sodium tetraborate buffer at
400 V/cm. Arrowhead: secondary antibody; Arrow: 8-OHdG complex. Top trace is offset
in the y-axis for the clarity.

To estimate the limits of detection, a calibration curve was constructed by plotting
the measurement of the average peak area (y) versus the amount of 8-OHdG (x) in Figure
24. The five-point calibration from 2.2 to 11 fmol showed the linear detection of 8-OHdG
with correlation coefficient of 0.96. The Equation 3 for the regression line is:
y = (1.23± 0.31)x10I5jc + (3.00±2.52);

R2 = 0.96

Eq. 3
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Figure 24: Electropherograms of calibration curve of 8-hydroxy-2'-deoxyguanosine (8OHdG) standard with different concentrations. Arrowhead: secondary antibody; Arrow:
8-OHdG complex. All the experimental conditions are the same as in Figure 23. Top
trace is offset in the y-axis for the clarity.

3.3.2

Analysis of 8-OHdG in Mice Urine
To illustrate the potential of this analytical method, we directly applied it to the

analysis of 8-OHdG in AD-Tg mice urine. We performed experiments using urine
samples from 11-month-old, male, transgenic mice. The electropherograms of the 8OHdG in urine and the standard is shown in Figure 25. This is a very fast and sensitive
method with an overall analytical run time of 10 min. The peaks at 164 s indicated the
identification of 8-OHdG in the urine sample. A good separation was obtained for 8OHdG complex from secondary antibody and complex of primary and secondary
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antibody. Based on Equation 3, and the measured peak area for the 8-OHdG peak, the
total 8-OHdG content in the injected volume for AD transgenic mice urine was calculated
as 0.51 fmole. For the CE analysis, only 0.31 nL volumes of samples were
hydrodynamically injected, which leads to urinary concentration of 8-OHdG of 1.64 |iM.
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Figure 25: Electropherograms of urine sample and 8-hydroxy-2'-deoxyguanosine (8OHdG) standard. Arrowhead: secondary antibody; Arrow: 8-OHdG complex. All the
experimental conditions are the same as in Figure 23.

The critical issue in detecting 8-OHdG in the urine sample is to avoid interference
from other compounds. This is achieved by using antibody that has high selectivity for 8OHdG compound. Among 500 papers published on urinary 8-OHdG detection, ELISA
method has been used primarily. There is ongoing debate whether the kit is specific to
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recognize other urine components than 8-OHdG. Toyokuni's group stated that the
antibody N45.1 is highly specific to 8-OHdG, showing weak or no cross reactivity with
the urine component such as uric acid, urea, creatine and creatinine [79]. Although it can
recognize both the modified base (8-oxoguanine) as well as the deoxyribose structure, the
modified base has to be at least two orders of magnitude higher in concentration to be a
competitor for the monoclonal antibody [79].
On the other hand, Song's group suggested that although ELISA is a very popular
technology for detection of 8-OHdG, it overestimated the amount of the antigen in the
samples, after examining 8-OHdG using both HPLC with ELISA [80]. They conclude
that one of the major reasons for the overestimation of urinary 8-OHdG detection in the
urine is caused by the cross reactivity of N45.1 with urea in the urine sample. Urea is
weakly recognized by the anti-8-OHdG antibody since both of them share a common NH-CO-N structure [80],
For our developed method, even if there were similar compounds in the urine and
cross reacted with the antibody, CE with high resolution and high sensitivity will offer
great promise to separate these interferences. For the capillary zone electrophoresis, the
borate buffer (a mixture of sodium tetraborate and boric acid) at pH 9.5 was employed.
Because at this pH level, the boric acid proton dissociation occurs, which further leads to
an increase in coupling sugar moiety of 8-OHdG with boric acid [81]. However, both
urea and creatinine are uncharged species, the transport of which is controlled by the
electroosmotic flow [81]. Therefore, the 8-OHdG and other possible interference can be
separated by charge to size ratio.

The urinary excretion of damaged nucleotides, 8-OHdG from both mtDNA and
nDNA serves as an essential biomarker of oxidative stress reflecting the rate of damage
in steady state. We have demonstrated this sensitive method combining both CE-LIF
separation and immuno-affinity characteristics capable of studying low abundant 8OHdG in small amount of urine sample. Because 8-OHdG is considered as a biomarker
of oxidative DNA damage, we cannot exclusively conclude that the results are only
related to AD. However, it allows us to determine oxidative status. Moreover, our results
clearly show the screening capability of 8-OHdG using this new developed method from
extracellular matrix (urine). The potential of using this method as a diagnostic biomarker
in AD progression in a larger set of subjects deserves further study. Additionally, this
method can serve as a tool to monitor the oxidative stress response of AD subjects with
therapeutic antioxidant treatment.
3.3.3

Assay Repeatability and Accuracy
The reproducibility of this method was evaluated with both injection and

analytical repeatabilities. To assess injection repeatability, five replicate injections of
labeled 8-OHdG were examined, while five different labeled 8-OHdG samples prepared
by the same procedure were studied for analytical repeatability. In the measurement of
analysis repeatability, the relative standard deviation (RSD) values for migration time and
peak area were 11.32% and 5.52%, respectively. In addition, day-to-day assays by
replicate injection of the 8-OHdG solution during five consecutive days were examined
to study the precision of the method. The RSD values of migration time and peak area
were 19.3% and 24.3%, respectively.

The accuracy was determined by performing a standard spiking method, where
known amounts of labeled 8-OHdG standard was mixed with analyzed 8-OHdG and
further detected by CE-LIF method in triplicate. The 8-OHdG LOD concentration of
28.61 nM was subsequently determined by the calibration curve. The percentage of the
spiked 8-OHdG recovered by the assay indicates the accuracy of the method was 93.14%.

CHAPTER 4

DISCUSSION

4.1

Glutathione Homeostasis

The aims of the present study were to quantify tissue glutathione (GSH and
GSSG) and S-glutathionylated protein (mixed-disulfides, Pr-SSG) levels in the brain and
blood at three ages (1-, 5- and 11-month-old) in a transgenic mice model of AD and
compared these levels to those found in wild type (WT) litter mates. In addition, tissue
differences in glutathione levels were investigated in the hippocampus, the cerebrum and
the cerebellum regions of Tg and WT brains.
As indicated in Figure 6, the absolute brain weight in 5-month WT mice was 12%
higher than their AD counterparts. Interestingly, the 11-month Tg mice demonstrated a
significant (20%) increase in brain weight as compared to WT animals at the same age.
Moreover, one-way ANOVA analysis showed that the total protein of AD-Tg brains
significantly increases from 2.5 (at 5-month-old) to 3.4 mg/ml (11-month-old) with
aging. The blood brain barrier (BBB) might be compromised in aged Tg mice, which
would contribute to increased fluid filtration, perhaps even serum protein from vessel
lumen to the brain. This suggestion is supported by previous autopsy finding that an
enhanced expression of aquaporin 4, the protein channels involved in water transport,
leads to edema formation in AD [82]. This interesting observation suggests an association
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of AD with brain inflammation, a subject of future investigation in our laboratory using
this AD mouse model.
4.1.1

Age Effect
In this work, we tried to address the hypothesis that oxidative stress, specifically,

the formation of GSSG and S-glutathionylated proteins is an early event prior to amyloid
plaque manifestation in AD progression. Our current use of 1 -month-old mice that have
not developed amyloid pathologies revealed that substantial increase in protein-thiol
oxidation (Pr-SSG formation) occurred in the absence of neuropathological markers, thus
supporting the view that an early loss of cerebral glutathione redox balance preceded
disease manifestation. Additional support comes from previous studies demonstrating
that the aging process is associated with the generation of reactive oxygen species and
disturbance of glutathione homeostasis in the brain [49, 83]. The 11-month-old aged mice
long after AfS generation represented a suitable model for AD progression. Our results
demonstrated significant age-related reduction of tissue GSH levels in the cerebrum and
associated decreases in the GSH/GSSG ratio in all brain regions from 5-month (right
before A(3 deposit) to 11-month, a stage when A(3 deposits are abundant. This age-related
decline in brain GSH level and the GSH/GSSG ratio is consistent with reduced GSH
synthesis, as evidenced by a decrease in y-glutamylcysteine ligase, the rate-limiting
enzyme in GSH synthesis during aging [84], Surprisingly, the brain GSSG levels in 5month-old mice were lower than 1-month-old, suggesting that the 5-month-old brain may
be more resistant to oxidative stress. The "dip-down" at 5-month was observed for both
GSSG and Pr-SSG levels with a corresponding increase in the GSH/GSSG ratio in all
brain regions. Thus, it appears that the transgenes induce a stress response to compensate

for its expression and this leads to an early increase in S-glutathionylation but the animals
reach an equilibrium, probably due to the large excess capacity at the middle age. Then
the response repeats during plaque deposition at a later stage.
The study of GSH redox state in blood not only serves as an index of oxidative
stress status, but also offers a comparison between age-related differences in GSH redox
status between the brain and blood. Interestingly, Pr-SSG was not detectable in the blood
of 1 -month-old mice, regardless of genotype; however, Pr-SSG levels were significantly
elevated in 5- and 11-month-olds, respectively. The summation of the total thiol pool
revealed that approximately 80-90% of blood thiols are in the form of oxidized disulfides
of which 40-50% are protein bound. Furthermore, the concentrations of GSH plus GSSG
in blood were 2-to-3 fold higher than those in brain tissues. It is notable that the level of
GSH was increased 1.6 fold in blood from 1- to 5-month-old in Tg mice. While the
significance of this increase is unresolved, typically higher blood GSH could act to
scavenge superoxide and hydroxyl radical.
The dramatic increase in Pr-SSG in blood at 5-month coupled to the dip in GSSG
and Pr-SSG in the brain (Figure 8) suggests an interesting scenario, namely, that an
increase in brain-to-blood export of GSSG at an age right before A(3 manifestation. The
consequent increase in systemic oxidative stress would be consistent with increased
formation of S-glutathionylated proteins (Pr-SSG) in the blood. It is not clear whether this
mixed-disulfide increase is primarily due to GSSG export from brain or perhaps
collectively from some other tissues such as the liver. Although these hypothetic
scenarios require further investigation and validation, it is confirmed by previous findings
that aging enhanced a cell's ability to export GSSG as a mechanism to maintain cellular
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redox homeostasis [85, 86]. Some of the proteins responsible for GSSG export have been
identified; reportedly, the multidrug resistant protein 1 (Mrpl) mediates GSSG efflux and
maintains GSH homeostasis. Mrpl is expressed in brain tissues, and has been implicated
in GSSG export in primary cultures of rat astrocytes [87] and mouse astrocytes [88].
Mrps function as organic anion export pumps, and accept glutathione ^-conjugates as
substrates [89-91]. Altogether, these results support the contention that oxidative stress
occurs before amyloid plaque deposition in AD brain, an early event in AD progression
[92-94]. Our current study suggests that intracellular brain GSH/GSSG status is
differentially regulated during AD progression, and that the rate of GSH synthesis and/or
GSSG export are likely to play important roles in cellular GSH redox homeostasis. Our
main goal of this study is to characterize glutathione redox status in details; and these
observations will further facilitate future studies into why these changes occur.
Particularly, we will investigate whether these changes in glutathione redox status are
closely related to the change in gamma-glutamylcysteine (for GSH synthesis) or MRP-1
(for GSH and GSSG export). Additionally, we will examine whether the change in
GSH/GSSG is attributed from apoptosis induced by amyloid aggregation.
4.1.2

Genotype Effect
The level of GSH in the cerebrum and the cerebellum of 11-month Tg mice were

decreased as compared to WT litter mates, while GSSG was elevated in 1- and 5-month
Tg animals. Moreover, the data in Figure 8 demonstrated the existence of significant
mixed-disulfides, suggesting that oxidative modification of protein thiols was evident in
various brain regions, most dramatically in Tg mice. For example, at 11-month, Sglutathionylated proteins (Pr-SSG) were substantially elevated in the three regions of the

brain and blood in Tg animals as compared to the WT counterpart. Even at 1-month old,
baseline Pr-SSG in Tg animals was higher than the WT counterpart, which might be due
to the fact of growth stress in Tg mice at an early stage before evidence of A|3 generation.
Plus, it is noteworthy that the content of protein-bound glutathione was variable, from 15
to 24 nmol/mg in the different brain regions of 11-month-old Tg animals and represented
a major percentage of total glutathione (range of free GSH was between 0.1 and 0.8
nmol/mg). Previous studies demonstrated a wide range in the GSH/GSSG ratio in the
brain, from 2 to 200, under conditions of oxidative stress, disease or aging [75,95, 96]. In
our study, the GSH/GSSG ratio ranged from 2 to 7; the ratio in all brain regions in aged
Tg mice (11-month olds) were significantly lower than their WT counterpart. This is
consistent with a relatively more oxidized basal intracellular environment and suggests
that the Tg brain would be selectively vulnerable to ROS damage.
4.1.3

Specific Brain Region Effect
The three brain tissues of the hippocampus, the cerebrum and the cerebellum were

examined to evaluate whether regional differences exist in cellular GSH redox status and
whether elevation in GSSG and Pr-SSG formation was associated with regional
vulnerability during AD progression. Notably, the basal level of Pr-SSG was high in the
hippocampus, even in the age-matched WT mice, suggesting that, regardless of genotype,
the hippocampus is likely to be a vulnerable region of the brain to oxidative stress.
Significantly, AD is associated with hippocampal damage and loss of cognitive functions
of the brain. Thus, the finding of altered tissue redox status before the onset of amyloid
plaque formation underscores the importance of evaluating redox changes at early stage
AD progression for early detection.
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GSH is present in millimolar (mM) concentrations in the brain [9]. However,
previous reports of GSH abundance among various brain regions were inconsistent [74,
75, 97], Studies by Zhu [75] and Liu [97] showed that GSH levels were similar in all
brain regions, including the cortex, the cerebellum and the hippocampus in SpragueDawley and Fisher 344 rats, respectively. In other studies, Abbott et al., reported that in
4-month-old mice, the levels of GSH varied in different anatomic regions of the brain
with the cortex exhibiting the highest value followed by the cerebellum and the
hippocampus [73, 74], However, our results indicate the cerebellum in both AD-Tg and
wild type mice have the highest GSH level among all the brain regions examined,
regardless of age difference (Figure 7). Interestingly, the cerebellum is the region of the
brain that is most resistant to age-associated AD pathology. The discrepancy between the
studies of Zhu and Liu [74, 75, 97] and those of Abbott et al. [73, 74] and our current
work could be due to species differences (rat vs. mice) as well as differences in animal
strains, housing, environmental and dietary factors. Although there were many
GSH/GSSG studies using AD mouse model [98-100], we have performed the
systematical measurements in differentiating the ROS induced GSH/GSSG and Pr-SSG
alternations using three aspects ~ age, genotypes and brain regions.
In summary, the present study has characterized the age-dependent status of
glutathione and mixed-disulfide in specific regions of the brain and blood of a transgenic
mouse model of AD, which provided the ground work for future investigation into the
relationship between GSH and A0 regulation, as well as into the mechanism of GSH
redox control in AD brain. The results will have important implication for age-dependent
and regional selective pathobiology of AD progression.
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To our knowledge, this is the first time such a study was undertaken and these
observations can serve as a supporting platform for future investigation. For example,
two opposite regimes, glutathione stimulator- N-acetyl-L-cysteine (NAC) and inhibitordiamine can be employed to further pinpoint whether alteration of GSH/GSSG ratio can
accelerate or decelerate amyloid plaque onset. Another interesting example will involve
studying how the fluctuation in GSH correlate with the change in NOX (NADPH oxidase
1/2), NOS (nitric oxide synthesis), and mitochondrial function. Altogether, an
understanding of regional and age differences in GSH and mixed-disulfide redox status
will provide important insights into differential antioxidant capacity and oxidative
susceptibility in the specific regions of AD brain.
The data from this study demonstrated that altered GSH redox balance in specific
brain regions is age- and genotype-linked in the transgenic model of AD (B6.Cg).
Collectively, the data shows that GSH redox imbalance and subsequent Sglutathionylation of proteins are early events, and provides a time line for when these
redox changes occur during AD progression. These results will underpin investigations
into the mechanism of AD-associated oxidative disruption of brain GSH homeostasis;
this information will be useful in future study of longitudinal changes in oxidative stress
and cognitive behavior in AD in this Tg mouse model.

4.2

Pr-SSG Profiles

The issue for the early screening of individuals who will progress to AD is a very
critical one. Although various imaging tools that facilitate the identification are present,
using capillary electrophoresis combined with PCA analysis to characterize oxidized
protein biomarkers would be a powerful tool. In our approach, we used principal
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component scores as quantitative markers for the each mouse S-glutathionylation
electrophoretic profile. The spatially distributed six groups in three dimensional PCA
plots were observed. Additionally, we used a cross validation method to determine the
use of principal component scores, and to predict the classification. This analysis
provides a great estimate at the early stage of AD progression.
4.2.1

Pr-SSG Electrophoretic Profiles
S-glutathionyl levels in brain tissues and blood samples of AD-Tg/WT mice at

different age stages were quantitatively determined using CGE-LIF. Overall, our study
demonstrated that Pr-SSG in AD-Tg mouse brain significantly increased with aging
except at 5-month-old. The difference of S-glutathionylation between Tg and WT
indicated that S-glutathionylation might be an early event prior to the AD progression.
The principal component scores, served as quantitative markers, were able to
discriminate AD from WT types, and even differentiate various AD staging groups.
We assessed the performance of S-glutathionylation profiles in the classification
of unknown samples. Specifically, we carried out a "leave-one-out" prediction for a "sixclass" prediction for "Alzheimer's" or "control" phenotype at the three disease
progression [101]. It was shown in Tables 5 and 6 that the sensitivity and accuracy of
using blood S-glutathionylation profiles appears suboptimal compared with brain
oxidative stress. Also, from PCA plot (Figure 18B), it was observed that the difference in
these six group classification was more pronounced in brain tissues than blood samples.
This observation may suggest that peripheral blood-based markers reflect mechanism of
the central nervous system (CNS) in AD, to some extent, but not completely. Peripheral
blood is a highly convenient source of biomarkers, which has been studied in research
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settings. However, it is unclear how and what proteins that originate as a result of brain
pathology, would be transited from the brain to the blood, since blood brain barrier may
limit the potential diagnostic blood-based markers to small or lipophilic molecules, or
ones with specific transporters [102].
However, it is notable that these observations of subpar prediction using blood Sglutathionylation profiles are only correct when including a consideration of AD
progression stages. Not considering AD staging but only predicting AD and non-AD
phenotypes, the most critical issue, the predicting specificity and sensitivity using blood
S-glutathionylation profiles reached 93.33% and 90.00%, respectively. Other reports have
also pointed to that the APP metabolism alteration and oxidative imbalance does not only
exist in neuronal plaque, but also in peripheral blood [103]. Hence, the oxidative
imbalance in the blood of AD subjects could mirror physiological events in CNS, to some
extent [104]. In our case, the change of blood S-glutathionylation profile is sufficient
enough to be detected and used for prediction. Even though brain proteins that pass into
the blood stream become diluted into a complex medium, it displays that our CGE-LIF
analytical method is sensitive to detect these low abundant oxidative stress related
biomarkers. These S-glutathionylated proteins can provide insight into processes such as
inflammation and oxidative damage. This study remains fully validated by future studies
such as determining key biomarkers to predict pathological diagnosis and further narrow
treatment options. Despite the absence of precise knowledge about the identity of these
biomarkers, we can still distinguish AD from non-AD, which is a very attractive feature
of this method. Our results show clinical usefulness of a panel of unknown biomarkers
associated with S'-glutathionylation from the blood.

4.2.2

Diagnostic Use
Surprisingly, the classification accuracy assessed for 5-month S-glutathionylation

spectral PCA analysis has great variance, while 1-month and 11-month mice have
significantly higher classification accuracy than random chance. This interesting finding
suggests that targeted oxidized proteins long before and long after amyloid plaque
deposition are indicative predictors of AD screening. However, immediately before
amyloid plaque formation, the oxidative stress induced S-glutathionylation becomes
ambiguous in terms of classification. This could be attributed by various factors, such as
antioxidant capacity surge to overcome the protein modification at 5-month right before
plaque deposition. What is more interesting is that our previous study of characterizing Sglutathionylation redox status showed that brain GSSG and Pr-SSG levels in 5-monthold mice were lower than 1-month-olds, suggesting that the 5-month-old brain may be
more resistant to oxidative stress [105]. Our electrophoretic spectra of targeted Sglutathionylation at 5-month-old seems to be agreeable to the previous observation on the
"dip-down" for Pr-SSG levels at 5 months, which suggests an abrupt change in the redox
status from its normal trend of increasing oxidative stress with aging. Thus, it appears
that the transgenes initially induce a stress response to compensate for its expression and
this leads to the early increase in S-glutathionylation, but the oxidative stress balance
reaches equilibrium, probably due to the large excess of antioxidant capacity at the
middle age. Then the response repeats during plaque deposition at the later stage. At this
end, our data suggests that 5-month (right before plaque manifestation) brain and blood
oxidative stress profile seems not completely reliable for AD and non-AD phenotype
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classification. Currently, it is unknown what precise mechanisms are involved in
oxidative stress at this stage.
On the other hand, we demonstrated the high accuracy of genotyping
classification at 1- and 11-month mice, based on PCA analysis of S-glutathionylated
proteins electrophoretic profiles. Our finding indicates that the measurement of molecular
weight based electrophoretic profiling of blood and brain S-glutathionylated proteins are
sensitive to change, even at the early stage of the disease long before the plaque
deposition. Also, our results highlight a unique method to use the electrophoretic
technique for separation of oxidized protein biomarkers and further analyze them with
PCA for monitoring the AD progression. We find that the electrophoretic characteristics
of oxidized proteins can serve as a predictor of AD progression and the early stage
screening.
4.2.3

Protein Biomarkers
To predict what Mw range indicates the most S-glutathionylated proteins

associated with aging and genotyping effects, the electropherograms were analyzed by
combining the loading vector of the first PC. The useful range extends up to 875 seconds
that corresponds to 277.9 kDa. The migration time of Pr-SSG in the brain and blood is
between 350 and 470 seconds which correspond to the Mw region at 8.4-20.3 kDa and
13.2-37.2 kDa, respectively. A previous proteome-based study showed that several key
proteins within these molecular weight ranges: Deoxyhemoglobin (15.8 kDa), acrystalline B (20.1 kDa) and GAPDH (36.1 kDa) were identified as S-glutathionylated
proteins with the loss of functions [16]. S-glutathionylation proteomics study in AD brain
shows the number of oxidized proteins increased and these identified proteins are
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involved in various cellular processes such as the glucose or energy metabolism, and
synaptic plasticity with loss of their functions [16]. These results indicate the Sglutathionylation involvement in AD brain and that it plays a key role in AD
pathogenesis.
Therefore, the particular Mw ranges of S-glutathionylated proteins predicted by
fast profiling from CGE-LIF and PCA could serve as a powerful tool to locate the
specific and precise Mw regions of interest. This prescreening would be instrumental for
complex global proteomic study because it helps tease out the most crucial biomarkers
within specific Mw range.
4.2.4

Spectral Separation
By focusing on proteins that are susceptible to oxidative stress, we were able to

identify AD phenotype. The simplicity and novelty of the method is that it allows the
simultaneous monitoring of all proteins with various expression levels of oxidative
damage, instead of investigating the abundance of each protein biomarker using various
biochemical assays such as ELISA, western blot or microarray. These biomarkers,
although unknown, are preferentially prone to S-glutathionylation in brain tissues and
blood samples. This method naturally investigates a panel of protein biomarkers that are
sensitive to S-glutathionylation. Besides, our omnibus measures of S-glutathionylated
proteome profiles with known abundance distribution as a function of Mw are promising
approaches for the development of blood-based diagnostic tests for AD. These proteins
are expected to have various functions such as (3-amyloid generation, the inflammatory
response and proteolytic inhibition. Compared with function imaging based AD

diagnosis, our method is less costly, so it is a great alternative addition to the AD
diagnosis.
Given the complexity implicated in AD pathogenesis, including amyloid plaque
formation, inflammation, oxidative stress disturbance [106, 107], and lipid metabolism
[108], the diagnostic accuracy of biomarkers may be improved by combining several
blood-based biomarkers related to different mechanisms [109]. Ray et al. found that a
panel of 18 signaling proteins in blood plasma together may indicate the early molecular
change in AD progression and are further used to identify MCI patients who progressed
to AD years later [110]. Hence, a confirmation in larger populations and an incorporation
of additional oxidative stress mechanisms such as carbonylation, nitrosylation and
nitration profiles may further improve the sensitivity and specificity of this approach.
4.2.5

Transgenic Mouse Model
Our chosen transgenic mouse model mostly mimics the early-onset Familial AD

(FAD) rather than the late-onset FAD because of APP and presenilin-1 (PS-1) genes
mutations [111] and the lack of ApoE-4 gene inheritance.
Since AD is a very complicated disease, it is a major obstacle to find an ideal
animal model that recapitulates the full spectrum of AD neuropathology, such as amyloid
plaques, tangles, cell dysfunction/loss and aging. Some aged primates and dogs exhibit
AD-like neuropathology; however, it is not practical to use them as models due to the
high cost and extensive time involved. Rodents, along with several other animal species
such as guinea pigs, Drosophila, Caenorhabditis elegans, and yeast have been considered
for AD research because they are relatively cheap to maintain and can be genetically
engineered. But none of these species develop AD pathology on aging [112], Among
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them, transgenic mice models are considered preferable because they have a similar
central nervous system (CNS) and the general neurobiology to humans. However, the
relative short time window (10 months) of AD-Tg mouse model could make some
challenges to studying the effect of aging. In addition, humans are less resistant to
neurotoxins and more easily develop AD with mutant APP compared to rodent models.
We know that the rodent models have not been able to effectively demonstrate all AD
aspects in a single animal [113].
In the end, it has been a significant limitation for the entire AD research field to
create an animal model that replicates the multiple AD characteristics [114]. Because of
this, currently we cannot simply relate the pathology resulted from the double mutation
expression in this artificial mouse model to an aged human brain.
Even though transgenic mice cannot represent all aspects of AD, our current
model helped us developed an invaluable tool for characterizing and detecting the
molecular changes in the ROS induced oxidative stress damage, particularly, Sglutathionylation in the early-onset FAD. This PCA analysis of S-glutathionylation
spectral profiles can be readily extrapolated to study the age effect on AD development
using a different animal model such as ApoE4 mice crossed with PD-APP mice [115,
116]. Most importantly, our method has great potential to analyze S-glutathionylation
profiles of human blood samples.

4.3

8-OHdG Detection

We developed a CE-LIF system to analyze urinary 8-OHdG. This method
demonstrates the detection and screening of 8-OHdG in urine using immuno-affinity
labeling coupled with CE-LIF. Our method is unique in that, (1) it reaches high

83

specificity with using CE separation method; plus, (2) it keeps the ease of use provided
by the immunoaffinity concept. The sample preparation can be completely excluded,
because it requires no solid phase extraction for urine. The ultrasensitive assay described
here is not limited to detection of 8-OHdG but can be expanded to other oxidative lesion
when appropriate affinity probes are available. Likewise, it has an enormous potential for
high throughput clinical applications as well as direct monitoring for the early diagnosis
and monitoring DNA oxidative stress progression.

APPENDIX A

CHEMICALS AND REAGENTS
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A.l

GSH and GSSG Determination

Mice identification tags were purchased from Hasco Tag in Dayton, KY. APP and
PSEN1 primers were from IDT, Coralville, Iowa. Master mix for PCR was from Idaho
Technology Inc., Salt Lake City, Utah. Grx was from IMCO in Stamford, CT. GSH and
GSSG were from Calbiochem. Diamide was from Research Organics Inc., Cleveland,
OH. Five 5'-Dithiobis (2-nitrobenzoic acid) (DTNB) was bought from Biosynth in Itasca,
IL. Iodoacetic acid (IAA), l-fluoro-2, 4-dinitrobenzen (FDNB) and triton X-100 were
obtained from Alfa Aesar in Ward Hill, MA. N-Ethylmaleimide (NEM), immobilized
TCEP disulfide reducing gel, bicinchoninic acid (BCA) protein assay kit was from
Thermo Scientific, Rockford, IL. Sodium dodecyl sulfate (SDS), sodium phosphate
diabasic, potassium phosphate monobasic, tris (hydroxymethyl)-aminomethane, tricine,
ethylenediaminetetraacetic acid (EDTA), sodium hydroxide, hydrochloric acid and
trichloroacetic acid (TCA) were all from Sigma, St. Louis, MO. Glutathione reductase
assay kit and glutathione peroxidase assay kit were both purchased from Cayman
Chemical Company in Ann Arbor, MI.

A.2
Sodium

dodecyl

sulfate

Pr-SSG Detection
(SDS),

2-[4-(2-hydroxyethyl)piperazin-l-yl]

ethanesulfonic acid (HEPES), ethylenediaminetetraacetic acid (EDTA), methanol,
sodium

hydroxide,

hydrochloric acid,

neocuproine, dextran

from

Leuconostoc

mesenteroides (average Mw 64-76 kDa), trypsin inhibitor (20 kDa), glyceraldehyde-3phosphate dehydrogenase (GAPDH, 36 kDa), albumin from chicken egg white (44 kDa),
bovine serum albumin (BSA, 66 kDa), bovine gamma globulin (BGG, 140 kDa),
trichloroacetic acid (TCA) were all from Sigma. Amicon ultra-4 (Mw cutoff of 3 kDa)
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spin columns were purchased from Millipore. Recombinant Grx-3 (CHS, C65Y) from
Escherichia coli was obtained from IMCO. Glutathione reductase (GR) was from Roche.
Nicotinamide adenine dinucleotide phosphate (NADPH), reduced glutathione (GSH), and
glutathione disulfide (GSSG) were all from Calbiochem. Diamide was from Research
Organics Inc. Five 5'-Dithiobis (2-nitrobenzoic acid) (DTNB) was from Biodynth. DLdithiothreitol (DTT) was from Fluka. Iodoacetic acid (IAA) and Triton X-100 were
obtained from Alfa Aesar. Ultra Trol dynamic pre-coat LN was from Target Discovery.
N-Ethylmaleimide (NEM), Dylight 488 maleimide, dimethyl sulfoxide (DMSO),
immobilized tris-2-carboxyethyl phosphate disulfide (TCEP) reducing gel, bicinchonic
acid (BCA) protein assay kit were all purchased from Thermo Scientific.

A.3

8-OHdG Detection

Aqueous solution of the reagents was prepared using 18 ohm water from Milli-Q
water purification system (Millipore, Bedford, MA). All chemicals were analytical grade
quality. 8-hydroxy-2-deoxyguanosine was purchased from Sigma-Aldrich (St. Louis,
MO). N45.1 anti 8-OHdG monoclonal antibody was obtained from Genox Corporation
(Baltimore, MD).

IgG Alexa fluor 488 goat secondary antibody was obtained from

Invitrogen (Ontario, Canada). Sodium tetraborate, DMSO, methanol, sodium hydroxide,
and hydrochloric acid were obtained from VWR International (Suwanee, GA).
Commercially flexible fused silica capillary was obtained from Polymicro Technologies
(Phoenix, AZ). The separation buffer consisted of 20 mM sodium tetraborate, pH 9.5.
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Dr. June Feng
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Dear Dr. Feng:
The Louisiana Tech University's Institutional Animal Care and Use Committee (IACUC) has
been carried out a review of your amended experimental protocol entitled:

Understanding the Molecular Mechanism of Alzheimer's Disease: Quantitative Proteomeics
of Oxidatively Modified Proteins using iTRAQ Analysis and a Novel Proteomic Reactor.

The proposed procedures have scientific merit and were found to provide reasonable and
adequate safeguards for the comfort of the animals, the safety of the researchers and the
participating students.
When you are prepared to order additional animals please contact me by e-mail to me at
jgspauld@latech.edu.
Please remember that you are required to keep adequate and accurate records of all procedures,
results, and the number of animals used in this protocol for three years after termination of the
project. These records must be available for review by the IACUC or state and federal animal
use agencies. Each year in October you will be required to complete a summary of animals used
for the United States Agricultural Agency (USDA). Note that failure to follow this protocol as
approved may result in the termination of research. If you have any questions please send e-mail
to me at iaspauld^latech.edu. This protocol must be submitted for renewal review in April

2012.
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